1
00:00:05,680 --> 00:00:10,320
>> TODAY'S MEETING WRITING TO

2
00:00:10,320 --> 00:00:15,240
 DR. PAULETTE GRAY EXECUTIVE

3
00:00:15,240 --> 00:00:17,440
SECRETARY OF THE NCAB WITHIN 10

4
00:00:17,440 --> 00:00:20,320
DAYS OF THE MEETING, ANY WRITTEN

5
00:00:20,320 --> 00:00:21,400
QUIETS OR STATEMENTS RECEIVED BY

6
00:00:21,400 --> 00:00:23,840
MEMBERS OF THE PUBLIC WILL

7
00:00:23,840 --> 00:00:25,920
RECEIVE CAREFUL CONSIDERATION,

8
00:00:25,920 --> 00:00:27,800
THE FOLLOWING MEMBERS ARE

9
00:00:27,800 --> 00:00:30,360
PARTICIPATING IN TODAY'S

10
00:00:30,360 --> 00:00:35,600
MEETING, DR. OSMAN, DR. HIEBERT,

11
00:00:35,600 --> 00:00:38,920
DR. P A SKETT, AND ARE THERE ANY

12
00:00:38,920 --> 00:00:40,440
QUESTIONS REGARDING PROCESS.

13
00:00:40,440 --> 00:00:46,080
>> HEARING NONE, DR. OLI-OSMAN,

14
00:00:46,080 --> 00:00:47,360
YOU MAY BEGIN THE MEETING.

15
00:00:47,360 --> 00:00:47,920
>> THANK YOU VERY MUCH.

16
00:00:47,920 --> 00:00:51,920
BEFORE WE START I WOULD LIKE TO

17
00:00:51,920 --> 00:00:53,560
REMIND US OF THE MANDATE OR

18
00:00:53,560 --> 00:00:57,160
MISSION STATEMENT OF THE AD HOC

19
00:00:57,160 --> 00:00:57,960
COMMITTEE ON GLOBAL HEALTH

20
00:00:57,960 --> 00:01:02,400
CANCER RESEARCH AND LET ME ALSO

21
00:01:02,400 --> 00:01:04,560
SAY THAT DR. CHAPP A S, WHENEVER

22
00:01:04,560 --> 00:01:07,360
HE JOINS, WE WILL TRY TO SQUEEZE

23
00:01:07,360 --> 00:01:11,120
HIM IN, SO THE PURPOSE OF THIS

24
00:01:11,120 --> 00:01:14,040
NCAB IS THE NCI DIRECTOR ON

25
00:01:14,040 --> 00:01:15,200
STRATEGIC APPROACHES AND

26
00:01:15,200 --> 00:01:17,280
OPPORTUNITIES TO ENHANCE NCI'S

27
00:01:17,280 --> 00:01:20,000
CONTRIBUTION TO GLOBAL CANCER

28
00:01:20,000 --> 00:01:20,280
RESEARCH.

29
00:01:20,280 --> 00:01:21,960
THIS GROUP WILL PROVIDE

30
00:01:21,960 --> 00:01:23,640
LEADERSHIP AND EXPERTISE WITH

31
00:01:23,640 --> 00:01:25,640
THE INTENTION OF OFFERING INPUT

32
00:01:25,640 --> 00:01:28,200
ON PROPOSING INITIATIVES AND

33
00:01:28,200 --> 00:01:29,280
CONCEPTS AND PARTNERSHIPS ALL

34
00:01:29,280 --> 00:01:31,920
PROVIDING INFORMATION TO HELP

35
00:01:31,920 --> 00:01:33,400
BEDETERMINE PRIORITIES OF NEW

36
00:01:33,400 --> 00:01:36,240
PROSPECTS FOR NCI AND GLOBAL

37
00:01:36,240 --> 00:01:36,600
CANCER RESEARCH.

38
00:01:36,600 --> 00:01:39,240
IN ADDITION THE SUBCOMMITTEE MAY

39
00:01:39,240 --> 00:01:40,400
SEARCH FOR NEW OPPORTUNITIES

40
00:01:40,400 --> 00:01:42,000
WHERE THE NCI CAN CONTRIBUTE

41
00:01:42,000 --> 00:01:43,760
INTERNATIONALLY, SUCH AS BY

42
00:01:43,760 --> 00:01:44,640
ADVANCING CLINICAL CANCER

43
00:01:44,640 --> 00:01:47,520
RESEARCH, BUILDING AND BRIDGING

44
00:01:47,520 --> 00:01:51,280
TECHNOLOGY, RESEARCH CAPACITY

45
00:01:51,280 --> 00:01:53,880
AND PROMOTING TRAINING PROGRAMS,

46
00:01:53,880 --> 00:01:55,760
SO IT'S QUITE A BROAD MANDATE

47
00:01:55,760 --> 00:01:59,040
AND ALLOWS US TO DO THINGS IN

48
00:01:59,040 --> 00:01:59,360
VARIOUS AREAS.

49
00:01:59,360 --> 00:02:01,200
SO, LET ME TAKE THE OPPORTUNITY

50
00:02:01,200 --> 00:02:07,720
TO WELCOME NEW MEMBERS TO THE

51
00:02:07,720 --> 00:02:08,720
SUBCOMMITTEE, I THINK YOU

52
00:02:08,720 --> 00:02:10,000
HAVEN'T GOTTEN THE FINAL LIST

53
00:02:10,000 --> 00:02:11,320
YET, BUT I THINK MOST OF HAVE

54
00:02:11,320 --> 00:02:15,120
YOU BEEN INFORMED OF IT.

55
00:02:15,120 --> 00:02:17,320
THE--AT THE LAST MEETING WHICH

56
00:02:17,320 --> 00:02:20,320
WAS HELD IN AUGUST OF LAST YEAR,

57
00:02:20,320 --> 00:02:23,520
JUST RIGHT AT THE NEXT SURGE OF

58
00:02:23,520 --> 00:02:25,760
THE COVID-19 EPIDEMIC, WE HAD

59
00:02:25,760 --> 00:02:29,080
THE OPPORTUNITY TO WELCOME

60
00:02:29,080 --> 00:02:30,320
DR. PATTY GRAVITZ, THE DEPUTY

61
00:02:30,320 --> 00:02:35,800
DIRECTOR OF THE CENTER AND TO

62
00:02:35,800 --> 00:02:38,520
GIVE US A RIVETTING PRESENTATION

63
00:02:38,520 --> 00:02:39,480
ON IMPLEMENTATION SCIENCE, I

64
00:02:39,480 --> 00:02:41,840
THINK SHE'S GOTTEN SEGHTSED NOW.

65
00:02:41,840 --> 00:02:43,240
TODAY'S MEETING WILL BE FAIRLY

66
00:02:43,240 --> 00:02:44,600
STRAIGHT FORWARD AND FOCUS ON 1

67
00:02:44,600 --> 00:02:46,720
TOPIC BUT BEFORE THRA, LET ME

68
00:02:46,720 --> 00:02:48,560
TAKE THE OPPORTUNITY TO WELCOME

69
00:02:48,560 --> 00:02:51,280
GUESTS AND IT WILL BE INTRODUCED

70
00:02:51,280 --> 00:02:56,960
LATER, JUST MENTIONED JUST NOW,

71
00:02:56,960 --> 00:02:57,960
DR. SAMIR, FROM THE INFECTIOUS

72
00:02:57,960 --> 00:03:00,880
DISEASES IN UGANDA AND

73
00:03:00,880 --> 00:03:02,120
DR. HANNAH SIMMONS, FROM

74
00:03:02,120 --> 00:03:03,120
[INDISCERNIBLE] UNIVERSITY OF

75
00:03:03,120 --> 00:03:04,520
SOUTH AFFRIC ATHEY WILL BE

76
00:03:04,520 --> 00:03:06,040
INTRODUCED LATER MORE IN THE

77
00:03:06,040 --> 00:03:06,640
MEETING.

78
00:03:06,640 --> 00:03:11,200
SO, AGAIN, TODAY'S MEETING WILL

79
00:03:11,200 --> 00:03:16,720
BE VERY FOCUSED, THE DOCTOR

80
00:03:16,720 --> 00:03:18,680
POWELL, THE DIRECTOR FOR THE

81
00:03:18,680 --> 00:03:19,520
CENTER FOR GLOBAL CANCER

82
00:03:19,520 --> 00:03:24,920
RESEARCH WILL GIVE US A BRIEF

83
00:03:24,920 --> 00:03:26,320
PRESENTATION ABOUT THE INSTITUTE

84
00:03:26,320 --> 00:03:27,720
AND HOPEFULLY AT THE NEXT

85
00:03:27,720 --> 00:03:29,280
MEETING, WE WILL HAVE MORE TIME

86
00:03:29,280 --> 00:03:31,600
FOR HIP TO UPDATE US.

87
00:03:31,600 --> 00:03:32,400
IT WOULD HAVE BEEN ALMOST 2

88
00:03:32,400 --> 00:03:34,560
YEARS IN THE JOB AS TO WHERE

89
00:03:34,560 --> 00:03:37,120
THINGS ARE GOING SO, WITHOUT

90
00:03:37,120 --> 00:03:41,120
MUCH ADO, I WILL CALL ON SATISH,

91
00:03:41,120 --> 00:03:42,640
TO GIVE US A BRIEF UPDATE AND

92
00:03:42,640 --> 00:03:45,120
THEN WE WILL MOVE ON TO THE MAIN

93
00:03:45,120 --> 00:03:49,120
PART OF THE PROGRAM.

94
00:03:49,120 --> 00:03:49,360
>> OKAY.

95
00:03:49,360 --> 00:03:51,080
I WILLS ASSUME EVERYONE CAN HEAR

96
00:03:51,080 --> 00:03:52,960
ME OKAY BUT LET ME KNOW IF NOT.

97
00:03:52,960 --> 00:03:55,360
THANK YOU SO MUCH FRANCIS FOR

98
00:03:55,360 --> 00:03:57,600
LETTING ME UPDATE THE

99
00:03:57,600 --> 00:03:59,560
SUBCOMMITTEE FROM THE CENTER FOR

100
00:03:59,560 --> 00:03:59,920
GLOBAL HEALTH.

101
00:03:59,920 --> 00:04:01,520
I WOULD BE BRIEF TODAY SINCE I

102
00:04:01,520 --> 00:04:03,320
HAD THE OPPORTUNITY TO UPDATE

103
00:04:03,320 --> 00:04:04,560
THE SUBCOMMITTEE WHEN WE MET

104
00:04:04,560 --> 00:04:05,880
LAST AUGUST AND WANTED TO SAVE

105
00:04:05,880 --> 00:04:07,720
TIME FOR OUR RPGHT SPEAKERS FOR

106
00:04:07,720 --> 00:04:08,920
THE ENSUING DISCUSSION AT THE

107
00:04:08,920 --> 00:04:10,120
END.

108
00:04:10,120 --> 00:04:10,640
NEXT SLIDE, PLEASE.

109
00:04:10,640 --> 00:04:12,640
SO LAST WEEK WAS A BUSY 1 FOR

110
00:04:12,640 --> 00:04:14,880
THE NCI AND FOR CGH AS I'M SURE

111
00:04:14,880 --> 00:04:17,720
ALL OF YOU ARE AWARE LAST

112
00:04:17,720 --> 00:04:44,680
WEDNESDAY ON FEBRUARY 2nd AS

113
00:04:44,680 --> 00:04:45,640
YOU MUST KNOW--CANCER THEME

114
00:04:45,640 --> 00:04:47,560
WHICH WAS SIMILARLY MET WITH

115
00:04:47,560 --> 00:04:49,320
VIBRANT WORLD WIDE ENGAGEMENT ON

116
00:04:49,320 --> 00:04:51,320
SOCIAL MEDIA AND ELSEWHERE, WE

117
00:04:51,320 --> 00:04:53,960
TOOK THIS OPPORTUNITY,

118
00:04:53,960 --> 00:04:56,760
CANCER.GOV TO DESCRIBE SOME OF

119
00:04:56,760 --> 00:05:00,200
OUR 2021 ACTIVITIES AND

120
00:05:00,200 --> 00:05:01,560
HIGHLIGHTS AT CGH AND THOSE OF

121
00:05:01,560 --> 00:05:03,920
YOU WHO CAN READ OUR STATEMENT

122
00:05:03,920 --> 00:05:19,320
AND WORLD CANCER STATEMENT. 

123
00:05:19,320 --> 00:05:20,440
NEXT SLIDE, PLEASE.

124
00:05:20,440 --> 00:05:21,040
--STRAY JECTORY TEENLIC PLAN

125
00:05:21,040 --> 00:05:23,040
WHICH IS NOW PUBLICLY AVAILABLE

126
00:05:23,040 --> 00:05:24,600
ON OUR WEBSITE WHICH WE

127
00:05:24,600 --> 00:05:26,200
PRESENTED PREVIOUSLY TO THIS

128
00:05:26,200 --> 00:05:31,840
GROUP WHICH WAS ACCOMPANIED BY A

129
00:05:31,840 --> 00:05:32,920
JAMA PUBLICATION WE WROTE ABOUT

130
00:05:32,920 --> 00:05:35,760
THE NEED TO PRIORITIZE CANCER IN

131
00:05:35,760 --> 00:05:38,160
2021 WITH GLOBAL HEALTH WHICH

132
00:05:38,160 --> 00:05:41,600
MAY HAVE BEEN SUFFICIENT IN 2011

133
00:05:41,600 --> 00:05:43,520
WHEN CGH WAS ESTABLISHED BUT IT

134
00:05:43,520 --> 00:05:44,800
IS NO LONGER SUFFICIENT GIVEN

135
00:05:44,800 --> 00:05:46,480
THE CURRENT AND FUTURE

136
00:05:46,480 --> 00:05:50,040
ANTICIPATED CANCER GLOBAL

137
00:05:50,040 --> 00:05:50,600
BURDEN. 

138
00:05:50,600 --> 00:05:51,040
NEXT SLIDE, PLEASE.

139
00:05:51,040 --> 00:05:52,520
IN RENEWING OUR VISION FOR THE

140
00:05:52,520 --> 00:05:54,480
CENTER, WE REFOCUSED OUR EFFORTS

141
00:05:54,480 --> 00:05:56,280
ON 4 PRIMARY GOAL AREAS WITH AN

142
00:05:56,280 --> 00:05:58,760
EMPHASIS ON LOW AND MIDDLE

143
00:05:58,760 --> 00:06:00,400
INCOME COUNTRIES, FOR CGH LED

144
00:06:00,400 --> 00:06:01,920
PROGRAMS, WE AIM TO SUPPORT

145
00:06:01,920 --> 00:06:03,160
RESEARCH THAT ADDRESSES THE

146
00:06:03,160 --> 00:06:06,960
ISSUES IN GLOBAL CANCER CONTROL

147
00:06:06,960 --> 00:06:08,720
OR LEVERAGES UNIQUE SCIENTIFIC

148
00:06:08,720 --> 00:06:12,520
OPPORTUNITIES ARISING FOR GLOBAL

149
00:06:12,520 --> 00:06:14,240
COLLABORATION, SUPPORTING GLOBAL

150
00:06:14,240 --> 00:06:15,480
RESEARCH TRAINING, PROMOTE

151
00:06:15,480 --> 00:06:16,240
SCIENCE DISSEMINATION FOR CANCER

152
00:06:16,240 --> 00:06:19,480
CONTROL AND WE NEED TO LEVERAGE

153
00:06:19,480 --> 00:06:21,080
GLOBAL PARTNERSHIPS WITH

154
00:06:21,080 --> 00:06:22,320
GOVERNMENTAL AND NONGOVERNMENTAL

155
00:06:22,320 --> 00:06:24,160
ORGANIZATIONS, WITHIN OUR

156
00:06:24,160 --> 00:06:25,720
RESEARCH PROGRAM, WE'RE

157
00:06:25,720 --> 00:06:27,480
CONCENTRATING ON SEVERAL APPLIED

158
00:06:27,480 --> 00:06:28,680
AREAS SHOWN ON THIS SLIDE.

159
00:06:28,680 --> 00:06:31,480
OUR FOCUS TODAY IS ON THE FIRST

160
00:06:31,480 --> 00:06:33,600
OF THESE MAIN EFFORTS TO SUPPORT

161
00:06:33,600 --> 00:06:36,280
INNOVATIVE AND CONTEXT

162
00:06:36,280 --> 00:06:37,920
APPROPRIATE TECHNOLOGIES FOR

163
00:06:37,920 --> 00:06:39,120
GLOBAL CANCER CONTROL, A MAIN

164
00:06:39,120 --> 00:06:41,360
STAY OF THESE EFFORTS IS THE

165
00:06:41,360 --> 00:06:42,240
AFFORDABLE CANCER TECHNOLOGIES

166
00:06:42,240 --> 00:06:43,920
PROGRAM WHICH IS A TRANSNCI

167
00:06:43,920 --> 00:06:46,920
PROGRAM THAT HAS BEEN ACTIVE

168
00:06:46,920 --> 00:06:49,480
SINCE 2013, IN DECEMBER TWEBT 20

169
00:06:49,480 --> 00:06:50,800
WEARY CEIVED APPROVAL FROM THE

170
00:06:50,800 --> 00:06:55,200
BSA TO REISSUE THE PROGRAM IN

171
00:06:55,200 --> 00:06:57,480
2021 EMPLOY OF NOTE THAT

172
00:06:57,480 --> 00:06:59,520
APPROVAL WAS REQUIRED WITHOUT A

173
00:06:59,520 --> 00:07:01,240
PRESENTATION WHICH WE REGUARDED

174
00:07:01,240 --> 00:07:02,520
AS A TREMENDOUS VOTE OF

175
00:07:02,520 --> 00:07:04,320
CONFIDENCE BUT ALSO A MISSED

176
00:07:04,320 --> 00:07:06,480
TIEWNTD TO HIGHLIGHT THE

177
00:07:06,480 --> 00:07:08,560
EXCITING PATIENT AND COMMUNITY

178
00:07:08,560 --> 00:07:10,120
CENTERED DEVELOPMENT IN LMICs

179
00:07:10,120 --> 00:07:11,080
THAT HAS BEEN ENABLED BY THE

180
00:07:11,080 --> 00:07:13,400
PROGRAM WHICH WAS RECOGNIZED BY

181
00:07:13,400 --> 00:07:15,240
AN NCI DIRECTOR'S AWARD IN 2021

182
00:07:15,240 --> 00:07:17,320
IN WHICH WE HOPE TO HIGHLIGHT

183
00:07:17,320 --> 00:07:18,840
THE SUBCOMMITTEE TODAY.

184
00:07:18,840 --> 00:07:21,120
AS FRANCIS MENTIONED I WILL

185
00:07:21,120 --> 00:07:22,400
REMIND SUBCOMMITTEE MEMBER AT

186
00:07:22,400 --> 00:07:26,640
OUR LAST MEET NOTHING AUGUST,

187
00:07:26,640 --> 00:07:28,120
DR. PATTY LED THE DISCUSSION

188
00:07:28,120 --> 00:07:30,400
EMPHASIZING THE EXCITING CANCER

189
00:07:30,400 --> 00:07:31,320
IMPLEMENTATION SCIENCE

190
00:07:31,320 --> 00:07:33,000
OPPORTUNITIES WHICH EXIST IN

191
00:07:33,000 --> 00:07:35,520
LMICs WHICH IS THE SECOND

192
00:07:35,520 --> 00:07:36,720
RESEARCH AREA ON THIS SLIDE.

193
00:07:36,720 --> 00:07:38,520
I WILL ALSO REMIND THE

194
00:07:38,520 --> 00:07:40,320
SUBCOMMITTEE THAT IN 2021 WE

195
00:07:40,320 --> 00:07:45,040
RECEIVED BSA APPROVAL FOR UR01

196
00:07:45,040 --> 00:07:46,920
AND U51 CONCEPTS TO SUPPORT THIS

197
00:07:46,920 --> 00:07:47,280
EMERGING FIELD.

198
00:07:47,280 --> 00:07:48,600
WE LOOK FORWARD TO SHARING

199
00:07:48,600 --> 00:07:49,960
PROGRESS AT FUTURE MEETING ABOUT

200
00:07:49,960 --> 00:07:52,040
THESE NEW PROGRAMS AMOUNTED TO

201
00:07:52,040 --> 00:07:57,040
LAUNCH IN 2022. 

202
00:07:57,040 --> 00:07:57,920
NEXT SLIDE, PLEASE.

203
00:07:57,920 --> 00:08:02,480
FINALLY BEFORE HANDING OVER TO

204
00:08:02,480 --> 00:08:04,120
DR. PEARMAN TO GIVE AN OVER VIEW

205
00:08:04,120 --> 00:08:05,080
OFLET TECHNOLOGIES PROGRAM, I

206
00:08:05,080 --> 00:08:06,400
WANT TO HIGHLIGHT SEVERAL

207
00:08:06,400 --> 00:08:07,320
UPCOMES EVENTS AND ACTIVITIES

208
00:08:07,320 --> 00:08:09,880
WHICH ARE LIKELY TO TRANSPIRE IN

209
00:08:09,880 --> 00:08:11,280
THE INTERVAL BEFORE THE

210
00:08:11,280 --> 00:08:11,960
SUBCOMMITTEE MEETS AGAIN.

211
00:08:11,960 --> 00:08:18,040
AS MENTIONED WE ARE EXCITED TO

212
00:08:18,040 --> 00:08:19,720
INITIATE U01 AND U54 PROGRAMS

213
00:08:19,720 --> 00:08:22,040
LATER THIS YEAR.

214
00:08:22,040 --> 00:08:24,120
WE ARE EXPANDING D43 GLOBAL

215
00:08:24,120 --> 00:08:25,000
INSTITUTIONAL RESEARCH TRAINING

216
00:08:25,000 --> 00:08:26,320
NETWORK WITH NEW AWARDS.

217
00:08:26,320 --> 00:08:28,240
WE ARE CURRENTLY ANALYZING

218
00:08:28,240 --> 00:08:31,080
RESPONSES FROM THE 2021 GLOBAL

219
00:08:31,080 --> 00:08:32,120
ONCOLOGY SURVEY OF NCI

220
00:08:32,120 --> 00:08:32,720
DESIGNATED CANCER CENTERS AND

221
00:08:32,720 --> 00:08:35,080
LOOK FORWARD TO SHARING THESE

222
00:08:35,080 --> 00:08:36,040
RESULTS SOON.

223
00:08:36,040 --> 00:08:38,520
WE'RE PLANNING THE TENTH ANNUAL

224
00:08:38,520 --> 00:08:39,920
SYMPOSIUM ON GLOBAL CANCER

225
00:08:39,920 --> 00:08:41,920
RESEARCH VIRTUALLY IN MARCH WITH

226
00:08:41,920 --> 00:08:44,840
THE ASCR, THE CONSORTIUM OF

227
00:08:44,840 --> 00:08:46,400
UNIVERSITIES FOR GLOBAL HEALTH

228
00:08:46,400 --> 00:08:47,880
AND SEVERAL NCI DESIGNATED

229
00:08:47,880 --> 00:08:52,440
CANCER CENTERS, THE SYMPOSIUM

230
00:08:52,440 --> 00:08:53,560
WILL HAVE EARLY INVESTIGATOR

231
00:08:53,560 --> 00:08:54,720
CAREER DAY THIS YEAR FOR THE

232
00:08:54,720 --> 00:09:05,000
FIRST TIME FOCUSED ON ASPIRING

233
00:09:05,000 --> 00:09:06,880
GLOBAL CANCER RESEARCHERS.

234
00:09:06,880 --> 00:09:08,680
IN 2022 GLOBAL CANCER RESEARCH

235
00:09:08,680 --> 00:09:11,200
AND CONTROL SEMINAR SERIES,

236
00:09:11,200 --> 00:09:11,840
GIVING TALKS INCLUDE

237
00:09:11,840 --> 00:09:14,440
THANKSGIVING MORNING WHO TALKS

238
00:09:14,440 --> 00:09:16,480
ABOUT FINANCIAL TOXICITY AFTER

239
00:09:16,480 --> 00:09:18,760
CANCER AND LMICs AND I HOPE

240
00:09:18,760 --> 00:09:20,520
SOME OF YOU WILL TUNE INTO SOME

241
00:09:20,520 --> 00:09:22,400
OF THESE AND LOOK FORWARD TO OUR

242
00:09:22,400 --> 00:09:23,680
PROGRESS IN THE DAYS AND MONTHS

243
00:09:23,680 --> 00:09:24,120
TO COME.

244
00:09:24,120 --> 00:09:25,720
THANK YOU FOR YOUR ATTENTION, IF

245
00:09:25,720 --> 00:09:28,920
IT'S OKAY, I WILL HAND IT OVER

246
00:09:28,920 --> 00:09:30,760
TO DR. PEARLANWHO'S SLIDES ARE

247
00:09:30,760 --> 00:09:35,920
IMMEDIATELY AFTER MINE.

248
00:09:35,920 --> 00:09:36,320
>> FANTASTIC.

249
00:09:36,320 --> 00:09:38,680
>> THANKS SATISH.

250
00:09:38,680 --> 00:09:40,880
>> I'M PAUL PEARLMAN AND I'M THE

251
00:09:40,880 --> 00:09:41,960
PROGRAM DIRECTOR FOR GLOBAL

252
00:09:41,960 --> 00:09:43,200
HEALTH TECHNOLOGY AND OVERSEE

253
00:09:43,200 --> 00:09:44,080
THE TECHNOLOGY RESEARCH.

254
00:09:44,080 --> 00:09:46,080
TODAY I'M HERE TO TALK ABOUT THE

255
00:09:46,080 --> 00:09:46,920
AFFORDABLE CANCER TECHNOLOGIES

256
00:09:46,920 --> 00:09:49,200
PROGRAM OR A. C. T. 

257
00:09:49,200 --> 00:09:51,280
NEXT SLIDE, PLEASE.

258
00:09:51,280 --> 00:09:53,680
THE ACT PROGRAM SUPPORTS

259
00:09:53,680 --> 00:09:54,440
TECHNOLOGY DEVELOPMENT FROM

260
00:09:54,440 --> 00:09:55,840
PROTOTYPE STAGE THROUGH CLINICAL

261
00:09:55,840 --> 00:09:56,960
IMPLEMENTATION STUDIES, ALL

262
00:09:56,960 --> 00:09:59,840
THAT'S PROJECTS ARE EXPECTED TO

263
00:09:59,840 --> 00:10:01,880
EXPLICITLY CONSIDER COST

264
00:10:01,880 --> 00:10:02,600
AFFORDABILITY AND COST

265
00:10:02,600 --> 00:10:03,840
EFFECTIVENESS IN LOCAL SETTINGS

266
00:10:03,840 --> 00:10:06,040
AS WELL AS COST OF DISPOSABLES

267
00:10:06,040 --> 00:10:07,720
AND REALITIES OF LOCAL SUPPLY

268
00:10:07,720 --> 00:10:08,160
CHAINS.

269
00:10:08,160 --> 00:10:09,320
INVESTIGATORS ARE REQUIRED TO

270
00:10:09,320 --> 00:10:10,520
FOCUS ON PREVENTIBLE OR

271
00:10:10,520 --> 00:10:12,720
TREATABLE CANCERS AND SPECIFIC

272
00:10:12,720 --> 00:10:14,440
LMIC SETTINGS AND DEMONSTRATE

273
00:10:14,440 --> 00:10:15,720
UTILITY OF THE PROPOSED

274
00:10:15,720 --> 00:10:16,920
TECHNOLOGY TO IMPROVE CANCER

275
00:10:16,920 --> 00:10:17,160
OUTCOMES.

276
00:10:17,160 --> 00:10:30,320
THIS MAY OR MAY NOT--CLIENT OR

277
00:10:30,320 --> 00:10:31,320
PATIENT INTERACTIONS AND COMPLEX

278
00:10:31,320 --> 00:10:32,160
HEALTH SYSTEMS.

279
00:10:32,160 --> 00:10:34,200
VALIDATION AND REAL WORLD HEALTH

280
00:10:34,200 --> 00:10:37,400
SETTINGS ALSO OFTEN LEADS TO

281
00:10:37,400 --> 00:10:37,840
ADDITIONAL ITERATIVE

282
00:10:37,840 --> 00:10:39,920
INNOVATIONS, THE A. C. T.

283
00:10:39,920 --> 00:10:44,200
PROGRAM FORMED A UNIQUE,

284
00:10:44,200 --> 00:10:49,800
MULTIDISCIPLINEAR SKPE BAKUGAN

285
00:10:49,800 --> 00:10:51,480
CROSS CULTURAL RESEARCH FOR

286
00:10:51,480 --> 00:10:53,320
SIGNIFICANT CANCER CONTROL

287
00:10:53,320 --> 00:10:54,800
CHALLENGES AND LMICs, THIS

288
00:10:54,800 --> 00:10:57,120
ACTS AS RESEARCH PROGRAMS AT THE

289
00:10:57,120 --> 00:10:57,760
NCLRKS I, ACTS FOCUSES ON

290
00:10:57,760 --> 00:10:59,760
PROJECT WHERE IS THERE'S ALREADY

291
00:10:59,760 --> 00:11:00,760
A WORKING PROTOTYPE WHETHER OR

292
00:11:00,760 --> 00:11:02,240
NOT THIS TECHNOLOGY HAS YET BEEN

293
00:11:02,240 --> 00:11:03,920
APPLIED TO A SPECIFIC CANCER,

294
00:11:03,920 --> 00:11:05,640
THE ADAPTATION OF THAT DEVICE OR

295
00:11:05,640 --> 00:11:08,800
ASSAY FOR A SPECIFIC CANCER AND

296
00:11:08,800 --> 00:11:09,960
THE LMIC SETTING FOLLOWED BY

297
00:11:09,960 --> 00:11:11,720
OPTIMIZATION OF THAT TECHNOLOGY

298
00:11:11,720 --> 00:11:18,000
AND ITS INTENDED USE SETTING.

299
00:11:18,000 --> 00:11:18,320
NEXT SLIDE.

300
00:11:18,320 --> 00:11:19,320
SATISH MENTIONED, IT'S GOOD TO

301
00:11:19,320 --> 00:11:21,400
NOTE THAT THIS PROGRAM IS A

302
00:11:21,400 --> 00:11:23,320
TRANSNCI EFFORT THAT INCLUDES

303
00:11:23,320 --> 00:11:25,840
PROGRAM EXPERTISE FROM ACROSS

304
00:11:25,840 --> 00:11:27,080
THE NCI, THE NIBIB HAS

305
00:11:27,080 --> 00:11:29,120
PARTICIPATED IN THE PROGRAM IN

306
00:11:29,120 --> 00:11:31,080
THE PAST.

307
00:11:31,080 --> 00:11:32,320
NEXT SLIDE.

308
00:11:32,320 --> 00:11:33,520
ACTS LEVERAGES A NUMBER OF

309
00:11:33,520 --> 00:11:34,920
PLATFORMS THAT ARE ENABLING A

310
00:11:34,920 --> 00:11:37,040
NEW GENERATION OF CARE

311
00:11:37,040 --> 00:11:38,800
TECHNOLOGIES TO ADDRESS LMICs

312
00:11:38,800 --> 00:11:39,400
AND HEALTH SYSTEMS.

313
00:11:39,400 --> 00:11:41,120
MANY OF THESE INNOVATIVE

314
00:11:41,120 --> 00:11:43,680
TECHNOLOGIES SUCH AS LAB ON A

315
00:11:43,680 --> 00:11:45,320
CHIP, LIQUID BIOPSY, NOVEL

316
00:11:45,320 --> 00:11:47,120
IMAGES, MODALITIES AND IMAGE

317
00:11:47,120 --> 00:11:47,960
ANALYSIS TOOLS, INCLUDING AI,

318
00:11:47,960 --> 00:11:50,360
JUST TO MAIM A FEW HAVE

319
00:11:50,360 --> 00:11:52,720
SIGNIFICANT POTENTIAL FOR IMPACT

320
00:11:52,720 --> 00:11:55,000
IN LMICs, RECENT DEVELOPMENTS

321
00:11:55,000 --> 00:11:56,480
AND CONSUMER ELECTRONICS, FIBRO

322
00:11:56,480 --> 00:11:58,120
FABRICATION AND CELL PHONE

323
00:11:58,120 --> 00:11:59,480
COMMUNICATIONS AND HAND HELD

324
00:11:59,480 --> 00:12:01,440
COMPUTERS FURLGTER IMPROVE THE

325
00:12:01,440 --> 00:12:03,720
PROSPECTS FOR SENSITIVE COST AND

326
00:12:03,720 --> 00:12:05,120
PORTABLE TECHNOLOGIES FOR CANCER

327
00:12:05,120 --> 00:12:05,320
CONTROL.

328
00:12:05,320 --> 00:12:07,120
WE ALSO RECOGNIZE THAT NEEDS

329
00:12:07,120 --> 00:12:09,720
OFTEN DRIVE OPPORTUNITIES FOR

330
00:12:09,720 --> 00:12:10,160
ACCELERATED TECHNOLOGY

331
00:12:10,160 --> 00:12:10,480
DEVELOPMENT.

332
00:12:10,480 --> 00:12:11,520
SO FOR INSTANCE ISSUES AROUND

333
00:12:11,520 --> 00:12:13,320
DISTANCE TO CARE AND CHAL

334
00:12:13,320 --> 00:12:14,680
ERVELGS WITH FOLLOW UP MAY BE

335
00:12:14,680 --> 00:12:16,360
MITIGATED IN PART BY TRUE POINT

336
00:12:16,360 --> 00:12:19,200
OF NEED DETECTION AND DIAGNOSTIC

337
00:12:19,200 --> 00:12:20,120
TECHNOLOGIES, UTILIZED AT THE

338
00:12:20,120 --> 00:12:22,240
PATIENT OR COMMUNITY LEVEL.

339
00:12:22,240 --> 00:12:23,760
MOLECULAR DIAGNOSTICS FOR

340
00:12:23,760 --> 00:12:26,520
SPECIFIC CANCERS ON ONCOGENIC

341
00:12:26,520 --> 00:12:28,720
VIRUSES AND TREATMENT MONITORING

342
00:12:28,720 --> 00:12:30,040
MAY ALLOW LEAP FROGGING OVER

343
00:12:30,040 --> 00:12:31,200
INFRASTRUCTURE WHERE APPROPRIATE

344
00:12:31,200 --> 00:12:33,120
AND FINALLY TECHNOLOGIES MAY BE

345
00:12:33,120 --> 00:12:34,560
ADDRESSED OR INTRODUCED TO

346
00:12:34,560 --> 00:12:36,400
ADDRESS CRITICAL WORKFORCE

347
00:12:36,400 --> 00:12:37,520
SHORTAGES BY SIMPLIFYING SAMPLE

348
00:12:37,520 --> 00:12:40,680
PREP OR MAYBE LEVERAGES AI TO

349
00:12:40,680 --> 00:12:43,200
AUTOMATE ROUTINE BURDENSOME

350
00:12:43,200 --> 00:12:45,520
TASKS, SO MUSEUM HAN EFFORT IS

351
00:12:45,520 --> 00:12:48,520
EXPENDED WHERE IT'S MOST NEEDED.

352
00:12:48,520 --> 00:12:49,320
NEXT SLIDE.

353
00:12:49,320 --> 00:12:50,920
THE ACTS PROGRAM SUPPORTS TEAM

354
00:12:50,920 --> 00:12:54,320
SCIENCE PROJECTS THAT ARE

355
00:12:54,320 --> 00:12:56,720
FOCUSED ON PREVENTING, DETECTING

356
00:12:56,720 --> 00:12:57,560
AND DIAGNOSING TREATED CANCERS

357
00:12:57,560 --> 00:12:59,920
IN LOCAL SYSTEMS THAT TAKES INTO

358
00:12:59,920 --> 00:13:01,520
ACCOUNT THE COMPLEXITY OF THAT

359
00:13:01,520 --> 00:13:02,640
HEALTH SYSTEM, OTHER DISEASE

360
00:13:02,640 --> 00:13:04,600
PRIORITIES AND REAL WORLD

361
00:13:04,600 --> 00:13:05,440
CONDITIONS, ACTS INVESTIGATORS

362
00:13:05,440 --> 00:13:06,760
ARE EXPECTED TO TAKE END USER

363
00:13:06,760 --> 00:13:08,480
DESIGN SERIOUSLY AS PART OF

364
00:13:08,480 --> 00:13:10,240
THEIR PROJECTS, FOCUSING ON COST

365
00:13:10,240 --> 00:13:11,520
AND,A FORDABLE BUT ALSO

366
00:13:11,520 --> 00:13:12,840
USABILITY, CONTEXT OF USE AND

367
00:13:12,840 --> 00:13:13,920
HOW THE INTERVENTION WILL

368
00:13:13,920 --> 00:13:15,800
EVENTUALLY BE TAKEN UP IN LOCAL

369
00:13:15,800 --> 00:13:16,920
COMMUNITIES.

370
00:13:16,920 --> 00:13:19,480
GIVEN THESE COMPLEXITS IT'S

371
00:13:19,480 --> 00:13:21,160
EXPECTED THAT ACTS EXPERTISE

372
00:13:21,160 --> 00:13:23,120
BRING EXPERTISE FROM THE DOMAIN

373
00:13:23,120 --> 00:13:23,760
ON ENGINEERING, ONCOLOGY PUBLIC

374
00:13:23,760 --> 00:13:25,360
HEALTH AND IN MANY CASES THE

375
00:13:25,360 --> 00:13:26,920
PRIVATE SEBLGHTOR TO BEAROT

376
00:13:26,920 --> 00:13:27,920
CANCER CONTROL CHALLENGES THEY

377
00:13:27,920 --> 00:13:31,760
SEEK TO ADDRESS.

378
00:13:31,760 --> 00:13:32,520
NEXT SLIDE.

379
00:13:32,520 --> 00:13:35,120
SO TO DATE THERE HAVE BEEN 3

380
00:13:35,120 --> 00:13:36,120
FUNDED FOAs AND 21 PROJECTS

381
00:13:36,120 --> 00:13:38,120
SUPPORTED IN THE ACTS PROGRAM.

382
00:13:38,120 --> 00:13:39,760
ALTHOUGH SEVERAL CURRENT

383
00:13:39,760 --> 00:13:42,000
PROJECTS ARE EXTENDED IN

384
00:13:42,000 --> 00:13:43,080
ACCORDANCE WITH NIH

385
00:13:43,080 --> 00:13:45,240
FLEXIBILITIES RELATED TO THE

386
00:13:45,240 --> 00:13:48,240
GLOBAL PANDEMIC, THE LAST OF

387
00:13:48,240 --> 00:13:49,280
THESE INVESTIGATORS WILL

388
00:13:49,280 --> 00:13:50,320
EFFECTIVELY CLOSE OUT THEIR

389
00:13:50,320 --> 00:13:52,080
PROJECTS IN APRIL OF 22, AT

390
00:13:52,080 --> 00:13:54,320
WHICH TIME A NEW COHORT WILL

391
00:13:54,320 --> 00:13:55,000
BEGIN THEIR PROJECTS.

392
00:13:55,000 --> 00:13:57,240
MORE THAN A HUNDRED ACTS

393
00:13:57,240 --> 00:13:59,000
PROJECTS HAVE BEEN INVITRO

394
00:13:59,000 --> 00:14:01,360
ASSAYS, MORE THAN A THIRD HAS

395
00:14:01,360 --> 00:14:02,280
BEEN FOR HIGHER QUAL TREATMENT

396
00:14:02,280 --> 00:14:03,720
FOR CANCER AND A FEW

397
00:14:03,720 --> 00:14:07,120
TECHNOLOGIES HAVE FOCUSED ON

398
00:14:07,120 --> 00:14:07,600
PORTABLE IMAGING.

399
00:14:07,600 --> 00:14:08,040
NEXT SLIDE.

400
00:14:08,040 --> 00:14:10,160
BECAUSE OF THE TEAM SCIENCE AND

401
00:14:10,160 --> 00:14:10,960
INTERNATIONAL NATURE OF THE

402
00:14:10,960 --> 00:14:13,520
PROGRAM, WE BELIEVE ACTS HAS

403
00:14:13,520 --> 00:14:15,400
HELPED PROVIDE NIH SUPPORT FOR

404
00:14:15,400 --> 00:14:17,320
HIGHLY DIVERSE COMMUNITY OF

405
00:14:17,320 --> 00:14:18,160
TECHNOLOGY FOCUSED

406
00:14:18,160 --> 00:14:18,520
INVESTIGATORS.

407
00:14:18,520 --> 00:14:20,800
ACTS KEY PERSONNEL UP IN 40%

408
00:14:20,800 --> 00:14:23,320
WOMEN WITH 38% OF THE PIs

409
00:14:23,320 --> 00:14:24,240
THEMSELVES BEING WOMEN, KEY

410
00:14:24,240 --> 00:14:27,720
PERSONNEL ON THE GRANTS ARE

411
00:14:27,720 --> 00:14:29,320
MAJORITY NONWHITE AND 32% OF

412
00:14:29,320 --> 00:14:31,240
NONPIs BEING WHITE AND FINALLY

413
00:14:31,240 --> 00:14:34,120
31% OF THE KEY PERSONNEL IN

414
00:14:34,120 --> 00:14:35,440
GRANTS ARE LMICs, TO CONTINUE

415
00:14:35,440 --> 00:14:36,920
BUILDING  ON THESE EFFORTS IN

416
00:14:36,920 --> 00:14:38,000
THE NEXT PHASE OF THE PROGRAM

417
00:14:38,000 --> 00:14:41,000
AND IN LINE WITH BROADER NCI

418
00:14:41,000 --> 00:14:42,200
EFFORTS TO DIVERSIFY THE

419
00:14:42,200 --> 00:14:43,600
SCIENTIFIC WORKFORCE WE

420
00:14:43,600 --> 00:14:45,520
EXPLICITLY REQUIRED THAT LMIC

421
00:14:45,520 --> 00:14:47,000
PERSONNEL BE INCLUDED ON KEY

422
00:14:47,000 --> 00:14:49,000
PERSONNEL ON FUTURE ACTS GRANTS,

423
00:14:49,000 --> 00:14:51,800
ENCOURAGE USE OF THE MULTIT. I.

424
00:14:51,800 --> 00:14:54,640
MECHANISM AND RARE SHARED PLANS

425
00:14:54,640 --> 00:14:56,360
THAT DEMONSTRATE HIGH INCOME AND

426
00:14:56,360 --> 00:14:57,680
LMIC INVESTIGATORS IN ALL

427
00:14:57,680 --> 00:15:00,920
APPLICATIONS AND REALLY

428
00:15:00,920 --> 00:15:01,960
IMPORTANTLY ESTABLISH IMPORTANT

429
00:15:01,960 --> 00:15:05,480
CRITERIA TIED TO THESE

430
00:15:05,480 --> 00:15:06,360
REQUIREMENTS.

431
00:15:06,360 --> 00:15:06,720
NEXT SLIDE.

432
00:15:06,720 --> 00:15:08,040
HAVE ABOUT BEEN SOME COMMON

433
00:15:08,040 --> 00:15:10,360
THEMES FOR THE ACTS PROJECT

434
00:15:10,360 --> 00:15:12,600
WHERE CANCER IS CONCERNED, NEW

435
00:15:12,600 --> 00:15:14,800
COUNTRY EXPERIENCES HAVE LED TO

436
00:15:14,800 --> 00:15:16,480
NEW DEVICES BETTER SUITED TO END

437
00:15:16,480 --> 00:15:18,360
USER ENVIRONMENTS AND EXTENDED

438
00:15:18,360 --> 00:15:19,520
ACTESS SOPHISTICATED OTHER

439
00:15:19,520 --> 00:15:20,000
TARGETS.

440
00:15:20,000 --> 00:15:21,280
LATER YOU WILL HEAR MORE ABOUT

441
00:15:21,280 --> 00:15:24,080
THIS WHERE THE TINY PLATFORM IS

442
00:15:24,080 --> 00:15:24,800
CONCERNED.

443
00:15:24,800 --> 00:15:26,160
PROJECT TEAMS COMPETED FOR

444
00:15:26,160 --> 00:15:29,640
ADDITIONAL FUNDING AND HELPED

445
00:15:29,640 --> 00:15:39,440
LARGE MULTINATIONAL CONSORTIA

446
00:15:39,440 --> 00:15:43,040
EXTENDING--IT'S ALSO IMPORTANT

447
00:15:43,040 --> 00:15:44,920
TO NOTE THAT 2 ACTS

448
00:15:44,920 --> 00:15:47,280
INVESTIGATORS GENERATED A KEY

449
00:15:47,280 --> 00:15:48,320
PERSPECTIVE DATA FOR

450
00:15:48,320 --> 00:15:50,280
THERMOCOAGULATION THAT WERE

451
00:15:50,280 --> 00:15:52,400
INCORPORATED INTO THE 2019 W. H.

452
00:15:52,400 --> 00:15:54,640
O. FOR CERVICAL TREATMENT OF

453
00:15:54,640 --> 00:15:55,240
PRECANCKER.

454
00:15:55,240 --> 00:15:57,560
DOE HAS SUPPORTED A LOT OF

455
00:15:57,560 --> 00:15:59,560
SUPPORT FOR RADIOACTIVE THERAPY

456
00:15:59,560 --> 00:16:02,320
PROJECTS AND USAID CREATED A

457
00:16:02,320 --> 00:16:06,120
STAND ALONE PROJECT WITH NCI

458
00:16:06,120 --> 00:16:08,680
SCALED INPUT TO ADDRESS CERVICAL

459
00:16:08,680 --> 00:16:12,680
CANCER IN MALAWI AND MOZAMBIQUE

460
00:16:12,680 --> 00:16:14,520
BASED PREVIOUS ON THE ACTS IN

461
00:16:14,520 --> 00:16:15,240
THE PREVIOUS PROGRAM.

462
00:16:15,240 --> 00:16:15,720
NEXT SLIDE.

463
00:16:15,720 --> 00:16:21,120
THIS YEAR WE PUT OUT A PROGRAM

464
00:16:21,120 --> 00:16:22,520
USING R21 MECHANISM IN CONTEXT

465
00:16:22,520 --> 00:16:25,440
OF THE IMAT PROGRAM RFAs, THE

466
00:16:25,440 --> 00:16:26,520
IMAT PROGRAM SPECIFICALLY

467
00:16:26,520 --> 00:16:27,920
TARGETS HIGH RISK, HIGH REWARD

468
00:16:27,920 --> 00:16:29,840
RESEARCH SO OUR GOAL WAS TO

469
00:16:29,840 --> 00:16:31,400
ENRICH FUTURE ACTS INVESTIGATOR

470
00:16:31,400 --> 00:16:32,840
POOLS WITH NEW APPROACHES,

471
00:16:32,840 --> 00:16:33,720
SPECIFICALLY BY USING THIS

472
00:16:33,720 --> 00:16:36,840
APPROACH, OUR GOAL IS TOUSHER IN

473
00:16:36,840 --> 00:16:38,200
NEW AND INNOVATIVE PLATFORMS AND

474
00:16:38,200 --> 00:16:40,120
THE ABILITY TO PROCESS MORE

475
00:16:40,120 --> 00:16:41,920
COMPLEX SAMPLES AND START TO USE

476
00:16:41,920 --> 00:16:43,840
THAT END USER DESIGNED INTO THE

477
00:16:43,840 --> 00:16:45,960
EARLIEST STAGES OF DESIGN OF NEW

478
00:16:45,960 --> 00:16:47,120
INTERVENTIONS, WE ALSO WORKED

479
00:16:47,120 --> 00:16:50,480
CLOSELY WITH THE NCI SMALL

480
00:16:50,480 --> 00:16:51,960
BUSINESS INNOVATION AND RESEARCH

481
00:16:51,960 --> 00:16:53,360
DEVELOPMENT CENTER FOR SEVERAL

482
00:16:53,360 --> 00:16:56,560
YEARS TO CREATE SEVERAL FUNDING

483
00:16:56,560 --> 00:16:57,600
OPPORTUNITIES FOR GLOBALLY

484
00:16:57,600 --> 00:16:58,920
DRIIVE HEALTH TECHNOLOGY

485
00:16:58,920 --> 00:17:00,160
RESEARCH AND TO DATE 15 AWARDS

486
00:17:00,160 --> 00:17:02,240
HAVE BEEN FUNDED TO THESESTS

487
00:17:02,240 --> 00:17:04,000
WITHSTAND ALONE P As AND

488
00:17:04,000 --> 00:17:05,200
APPLICATIONS CONTINUE TO COME IN

489
00:17:05,200 --> 00:17:07,680
THIS RESPONSE TO A NOSI THAT HAS

490
00:17:07,680 --> 00:17:08,640
THE SAME INTENT.

491
00:17:08,640 --> 00:17:10,880
WE ARE ALSO LEVERAGING THE

492
00:17:10,880 --> 00:17:12,720
CONTACT TOPIC MEMORY RESPONSE

493
00:17:12,720 --> 00:17:16,120
NICKER TO FOCUS ON TOPICS SUCH

494
00:17:16,120 --> 00:17:17,640
AS COMMERCIALLY DRIVEN POINT OF

495
00:17:17,640 --> 00:17:20,720
DIAGNOSTICS TO SERVE THE BROADER

496
00:17:20,720 --> 00:17:21,720
ELIMINATION GOALS, ALL OF THESE

497
00:17:21,720 --> 00:17:23,760
HAVE ALLOWED FOR PHASE 1, AND

498
00:17:23,760 --> 00:17:27,160
PHASE 2 AWARDS. 

499
00:17:27,160 --> 00:17:28,920
NEXT SLIDE.

500
00:17:28,920 --> 00:17:31,000
FOLLOWING A FAVORABLE EXTERNAL

501
00:17:31,000 --> 00:17:32,280
PROGRAM REVIEW AND ENTHUSIASTIC

502
00:17:32,280 --> 00:17:33,720
SUPPORT FROM THE NCI LEADERSHIP

503
00:17:33,720 --> 00:17:35,920
AND THE BSA, AT THE

504
00:17:35,920 --> 00:17:37,240
DECEMBER 2020 JOINT BOARD

505
00:17:37,240 --> 00:17:38,600
MEETING, WE WERE CERTAINLY

506
00:17:38,600 --> 00:17:39,920
THRILLED TO REISSUE THE ACTS

507
00:17:39,920 --> 00:17:43,720
PROGRAM LAST YEAR USING A U01

508
00:17:43,720 --> 00:17:45,560
COOPERATIVE AGREEMENT MECHANISM.

509
00:17:45,560 --> 00:17:46,400
THESE U01 GRANTS CONTINUE TO

510
00:17:46,400 --> 00:17:48,920
SHARE THE FOCUS OF THE PREVIOUS

511
00:17:48,920 --> 00:17:50,720
ACCESS FOAs BUT ARE A CLEAR

512
00:17:50,720 --> 00:17:52,520
FOCUS ON CLINICAL VALIDATION AND

513
00:17:52,520 --> 00:17:54,120
HEALTH SYSTEMS INTEGRATION WHILE

514
00:17:54,120 --> 00:17:55,080
LEADING BUSINESS DEVELOPMENT

515
00:17:55,080 --> 00:17:57,400
ASPECTS TO OTHER RELEVANT

516
00:17:57,400 --> 00:17:58,200
INITIATIVES.

517
00:17:58,200 --> 00:18:00,240
THE FIRST RFA IN THIS SERIES WAS

518
00:18:00,240 --> 00:18:01,680
PUBLISHED LAST MARCH, EXPIRED IN

519
00:18:01,680 --> 00:18:05,160
JUNE AND 7 NEW AWARDS WILL BE

520
00:18:05,160 --> 00:18:07,080
ISSUED THIS SPRING.

521
00:18:07,080 --> 00:18:09,120
WE EXPECT 2 SUBSEQUENT ANNUAL

522
00:18:09,120 --> 00:18:09,360
ISSUANCES.

523
00:18:09,360 --> 00:18:14,120
NEXT SLIDE. 

524
00:18:14,120 --> 00:18:15,400
NEXT SLIDE, PLEASE.

525
00:18:15,400 --> 00:18:17,160
AT THIS POINT I WOULD LIKE TO

526
00:18:17,160 --> 00:18:19,600
WELCOME OUR INVITED GUESTS WHO

527
00:18:19,600 --> 00:18:20,520
CONDUCTED TRULY EXCITING WORK

528
00:18:20,520 --> 00:18:23,080
THROUGH THE FIRST PHASE OF THE

529
00:18:23,080 --> 00:18:23,800
ACTS PROGRAM--

530
00:18:23,800 --> 00:18:24,080
>> PAUL?

531
00:18:24,080 --> 00:18:27,120
>> YES, SIR.

532
00:18:27,120 --> 00:18:29,720
>> IF YOU WOULD PERMIT ME, I

533
00:18:29,720 --> 00:18:30,480
WOULD LIKE TO--BEFORE WE MOVE

534
00:18:30,480 --> 00:18:36,520
OVER TO OUR GUESTS TO TAKE SOME

535
00:18:36,520 --> 00:18:37,480
QUESTIONS SATISH AND YOU AND

536
00:18:37,480 --> 00:18:39,160
THEN CLOSE THAT SECTION AND THEN

537
00:18:39,160 --> 00:18:40,520
YOU GET BACK AND INTRODUCE THE

538
00:18:40,520 --> 00:18:45,240
GUESTS, WOULD THAT WORK?

539
00:18:45,240 --> 00:18:46,320
>> YES, SIR.

540
00:18:46,320 --> 00:18:47,080
>> YEAH, OKAY.

541
00:18:47,080 --> 00:18:50,160
SO THAT MAKES IT SMOOTH THEN.

542
00:18:50,160 --> 00:18:52,520
I'LL OPEN THE MEETING NOW FOR

543
00:18:52,520 --> 00:18:55,280
QUESTIONS TO DR. GOP A L'S

544
00:18:55,280 --> 00:18:58,080
INITIAL PRESENTATION AND ALL TO

545
00:18:58,080 --> 00:19:00,240
THE AFFORDABLE CANCER

546
00:19:00,240 --> 00:19:03,080
TECHNOLOGIES PROGRAM OVERVIEW BY

547
00:19:03,080 --> 00:19:05,120
DR. PEARLMAN, SO IF YOU HAVE ANY

548
00:19:05,120 --> 00:19:07,040
QUESTIONS SPECIFICALLY TO THOSE

549
00:19:07,040 --> 00:19:07,640
MORE GENERALIZED PRESENTATION,

550
00:19:07,640 --> 00:19:13,320
WE CAN TAKE THEM NOW.

551
00:19:13,320 --> 00:19:18,600
>> WELL I WILL START OFF WITH A

552
00:19:18,600 --> 00:19:21,840
COMMENTARY ON THE--SA ATISH, YOU

553
00:19:21,840 --> 00:19:24,320
DID MENTION THE GLOBAL HEALTH

554
00:19:24,320 --> 00:19:25,040
CANCER SYMPOSIUM THAT YOU'RE

555
00:19:25,040 --> 00:19:25,840
PLANNING AND I THINK YOU SAID

556
00:19:25,840 --> 00:19:28,120
YOU WERE GOING TO ENGAGE OR YOU

557
00:19:28,120 --> 00:19:33,040
ARE ENGAGED IN THE ACR,

558
00:19:33,040 --> 00:19:34,720
ASCO-ACS, IN IT, I THINK IT'S

559
00:19:34,720 --> 00:19:37,000
FANTASTIC BECAUSE AS YOU KNOW,

560
00:19:37,000 --> 00:19:38,600
THEY HAVE VERY--ALL OF THEM ARE

561
00:19:38,600 --> 00:19:40,040
ACTIVE ON A GLOBAL STAGE WITH

562
00:19:40,040 --> 00:19:41,640
DIFFERENT PROGRAMS AND THE MORE

563
00:19:41,640 --> 00:19:43,600
THOSE CAN BE LEVERAGED AND

564
00:19:43,600 --> 00:19:49,720
INTERACTED WITH, THE MORE THAT

565
00:19:49,720 --> 00:19:50,400
WOULD BE GREAT.

566
00:19:50,400 --> 00:19:53,120
OH HERE'S A COMMENT.

567
00:19:53,120 --> 00:19:54,840
TO DR. PEARLMAN, I'M WONDERING

568
00:19:54,840 --> 00:20:01,120
HOW MANY OF THE TECHNOLOGIES,

569
00:20:01,120 --> 00:20:03,440
THE APPS THAT HAVE BEEN FUNDED

570
00:20:03,440 --> 00:20:04,960
THROUGH THIS PROGRAM HAVE MOVED

571
00:20:04,960 --> 00:20:07,280
ON TO COMMERCIALIZATION OR AT

572
00:20:07,280 --> 00:20:08,360
LEAST THE SBIR STAGE GIVEN A

573
00:20:08,360 --> 00:20:15,080
SENSE  HOW SUCCESSFUL IT'S BEEN?

574
00:20:15,080 --> 00:20:16,840
>> WELL, THE SBIRs ARE

575
00:20:16,840 --> 00:20:18,680
CERTAINLY RESTRICTED ONLY TO

576
00:20:18,680 --> 00:20:20,480
U.S. SMALL BUSINESS INTEREST SO

577
00:20:20,480 --> 00:20:23,800
IN MANY WAYS THE SBIR FUNDING TO

578
00:20:23,800 --> 00:20:28,560
DATE HAS BEEN PARALLEL TO THE

579
00:20:28,560 --> 00:20:29,480
PREVIOUS COOPERATIVE AGREEMENT

580
00:20:29,480 --> 00:20:32,480
AWARDS THAT WERE FUNDED IN THE

581
00:20:32,480 --> 00:20:33,720
ACTS PROGRAM, SOME--A COUPLE OF

582
00:20:33,720 --> 00:20:35,760
THE INVESTIGATORS HAVE

583
00:20:35,760 --> 00:20:36,600
SUCCESSFULLY SOUGHT SBIRs TO

584
00:20:36,600 --> 00:20:42,120
FURTHER SOME OF THOSE

585
00:20:42,120 --> 00:20:50,160
TECHNOLOGIES BUT THE

586
00:20:50,160 --> 00:20:53,040
REALITY--INTO SORT OF COMMERCIAL

587
00:20:53,040 --> 00:20:54,080
DEVELOPMENT OR MANUFACTURING.

588
00:20:54,080 --> 00:20:55,000
I WOULD SAY THAT IF YOU'RE

589
00:20:55,000 --> 00:20:57,920
LOOKING AT SORT OF BENCHMARKS

590
00:20:57,920 --> 00:20:59,720
FOR COMMERCIAL SUCCESS, IT'S

591
00:20:59,720 --> 00:21:01,480
LARGELY BEEN THE LICENSING OF

592
00:21:01,480 --> 00:21:02,520
TECHNOLOGIES TO DATE WHICH IS

593
00:21:02,520 --> 00:21:05,880
TRUE OF MANY OF THE

594
00:21:05,880 --> 00:21:06,200
TECHNOLOGIES.

595
00:21:06,200 --> 00:21:09,000
>> YOU HAVE A FEW OF THOSE?

596
00:21:09,000 --> 00:21:12,240
>> YEAH, CERTAINLY MANY HAVE

597
00:21:12,240 --> 00:21:14,120
BEEN LICENSED TO THEIR INITIAL

598
00:21:14,120 --> 00:21:15,880
BUSINESS PARTNERS OR TO OTHER

599
00:21:15,880 --> 00:21:18,000
COMPANIES.

600
00:21:18,000 --> 00:21:18,800
>> I SEE, THAT'S INTERESTING.

601
00:21:18,800 --> 00:21:30,680
ANY OTHER QUESTIONS OR COMMENTS?

602
00:21:30,680 --> 00:21:31,120
>> HELLO, THIS IS

603
00:21:31,120 --> 00:21:32,320
[INDISCERNIBLE] I'M FROM HOPKINS

604
00:21:32,320 --> 00:21:34,160
I'M 1 OF NEW BOARD MEMBERS.

605
00:21:34,160 --> 00:21:35,480
CANCER CENTERS HAVE INITIATIVES

606
00:21:35,480 --> 00:21:36,760
IN THE GLOBAL HEALTH SPACE THAT

607
00:21:36,760 --> 00:21:39,160
ARE BOTH, AT THE PILOT LEVEL OR

608
00:21:39,160 --> 00:21:41,880
LARGER INITIATIVES THAT ARE DONE

609
00:21:41,880 --> 00:21:43,080
IN COLLABORATION WITH SOME OF

610
00:21:43,080 --> 00:21:45,800
THE--COUNTRYS ON THE OUTSIDE OR

611
00:21:45,800 --> 00:21:48,240
OTHER INSTITUTIONS, IS THERE ANY

612
00:21:48,240 --> 00:21:49,520
DISCREET STRUCTURE TO KNOW AND

613
00:21:49,520 --> 00:21:51,240
KEEP TRACK OF PROJECTS THAT ARE

614
00:21:51,240 --> 00:21:53,720
BEING DONE OUTSIDE OF NCI

615
00:21:53,720 --> 00:21:57,080
FUNDING BUT THAT CAN INFORM NCI

616
00:21:57,080 --> 00:21:57,360
PROJECTS?

617
00:21:57,360 --> 00:21:59,000
BECAUSE MANY OF THOSE CAN BE

618
00:21:59,000 --> 00:22:02,320
LARGE IN SCALE.

619
00:22:02,320 --> 00:22:04,600
>> SATISH, YOU WANT TO TAKE THAT

620
00:22:04,600 --> 00:22:04,760
ON?

621
00:22:04,760 --> 00:22:05,640
>> YES, THANK YOU IF ARE YOUR

622
00:22:05,640 --> 00:22:06,760
QUESTION, SO WE WORK VERY

623
00:22:06,760 --> 00:22:10,160
CLOSELY WITH THE CANCER CENTERS,

624
00:22:10,160 --> 00:22:11,200
TYPICALLY EVERY 2 YEARS WE

625
00:22:11,200 --> 00:22:12,600
SURVEY THE CANCER CENTERS TO GET

626
00:22:12,600 --> 00:22:14,640
A SENSE OF ALL OF THE ACTIVITY

627
00:22:14,640 --> 00:22:17,520
YOU JUST ALLUDED TO, THAT IS

628
00:22:17,520 --> 00:22:19,840
OCCURRING IN GLOBAL ONCOLOGY,

629
00:22:19,840 --> 00:22:21,400
THE STUFF THAT IS NIH SUPPORTED

630
00:22:21,400 --> 00:22:22,920
IS VERY EASY FOR US TO TRACK BUT

631
00:22:22,920 --> 00:22:24,560
AS YOU KNOW MANY CANCERS ARE

632
00:22:24,560 --> 00:22:26,560
DOING A LOT WITH PHILANTHROPIC

633
00:22:26,560 --> 00:22:27,840
AND OTHER SUPPORT THAT IS LESS

634
00:22:27,840 --> 00:22:30,000
EASY FOR US TO TRACK.

635
00:22:30,000 --> 00:22:31,360
WE HAVE A REALLY GOOD SURVEY,

636
00:22:31,360 --> 00:22:34,640
KIND OF INSTRUMENT THAT WE HONED

637
00:22:34,640 --> 00:22:35,880
OVER MANY YEARS.

638
00:22:35,880 --> 00:22:37,640
WE FIELDED IT LAST YEAR BUT

639
00:22:37,640 --> 00:22:38,560
ESSENTIALLY A HUNDRED PERCENT

640
00:22:38,560 --> 00:22:40,040
RESPONSE RATE FROM THE CANCER

641
00:22:40,040 --> 00:22:40,280
CENTERS.

642
00:22:40,280 --> 00:22:42,400
SO WE'RE IN THE PROCESS OF

643
00:22:42,400 --> 00:22:43,200
ANALYZING AND DISSEMINATING THAT

644
00:22:43,200 --> 00:22:43,680
INFORMATION NOW.

645
00:22:43,680 --> 00:22:45,600
WE WILL LOOK FORWARD TO

646
00:22:45,600 --> 00:22:48,320
REPORTING THAT OUT TO THIS GROUP

647
00:22:48,320 --> 00:22:49,160
LATER THIS YEAR.

648
00:22:49,160 --> 00:22:51,280
WITH THE LAST ROUND, WHEN WE DID

649
00:22:51,280 --> 00:22:53,360
THAT WHICH WAS 2018/2019, ONCE

650
00:22:53,360 --> 00:22:56,520
WE ANALYZED THOSE RESULTS,

651
00:22:56,520 --> 00:22:59,160
THERE'S A PAPER ON JCO GLOBAL

652
00:22:59,160 --> 00:23:00,640
SUMMARIZING THOSE RESULTS.

653
00:23:00,640 --> 00:23:01,720
WE DISSEMINATED THEM QUITE

654
00:23:01,720 --> 00:23:05,640
WIDELY INCLUDING TO THIS GROUP

655
00:23:05,640 --> 00:23:08,160
TO ASCO, TO AACR, WE MADE A

656
00:23:08,160 --> 00:23:10,360
PRESENT ANTICIPATION AT THE

657
00:23:10,360 --> 00:23:11,760
CANCER CENTER DIRECTOR'S ANNUAL

658
00:23:11,760 --> 00:23:12,920
MEETING, FOLLOWING WHICH MANY OF

659
00:23:12,920 --> 00:23:14,160
THEM WANTED TO REACH OUT

660
00:23:14,160 --> 00:23:16,080
SPECIFICALLY TO SPEAK ABOUT THE

661
00:23:16,080 --> 00:23:17,040
GLOBAL ONCOLOGY PROGRAM SO WE

662
00:23:17,040 --> 00:23:18,040
ARE LOOKING FORWARD TO HAVING

663
00:23:18,040 --> 00:23:18,720
THOSE RESULTS FOR YOU LATE

664
00:23:18,720 --> 00:23:21,040
THERAPY AND YEAR AND ALSO USING

665
00:23:21,040 --> 00:23:22,760
THE DISSEMINATION AS AN

666
00:23:22,760 --> 00:23:24,720
OPPORTUNITY TO REENGAGE WITH

667
00:23:24,720 --> 00:23:26,400
CANCER CENTERS TO SPEZZIFY WE

668
00:23:26,400 --> 00:23:28,360
CAN BETTER INCEND VISE AND

669
00:23:28,360 --> 00:23:32,520
SUPPORT THESE KINDS OF EFFORTS.

670
00:23:32,520 --> 00:23:33,480
>> RIGHT AND SATISH, YOU THINK

671
00:23:33,480 --> 00:23:35,120
YOU CAN MAKE A NOTE TO CIRCULATE

672
00:23:35,120 --> 00:23:39,120
TO MEMBERS OF THE SUBCOMMITTEE

673
00:23:39,120 --> 00:23:42,120
THE JCR PUBLICATION?

674
00:23:42,120 --> 00:23:42,400
>> SURE.

675
00:23:42,400 --> 00:23:45,920
>> FRANK, COULD I ASK A QUICK

676
00:23:45,920 --> 00:23:46,320
QUESTION.

677
00:23:46,320 --> 00:23:47,720
>> SURE MARGARET.

678
00:23:47,720 --> 00:23:50,240
>> TO DR. PEARLMAN, YOU

679
00:23:50,240 --> 00:23:59,120
MENTIONED THERE WERE SEVERAL

680
00:23:59,120 --> 00:24:00,760
INVITROW ASSAYS, I WAS WONDING

681
00:24:00,760 --> 00:24:02,920
WHAT THEY WERE AND THEIR

682
00:24:02,920 --> 00:24:04,880
RELEVANCE TO LMIC COUNTRIES,

683
00:24:04,880 --> 00:24:05,080
SORRY.

684
00:24:05,080 --> 00:24:07,640
JUST WONDERED ABOUT THAT.

685
00:24:07,640 --> 00:24:07,920
>> SURE.

686
00:24:07,920 --> 00:24:09,640
HAPPY TO RESPOND DR. SPITZ.

687
00:24:09,640 --> 00:24:11,520
THEY RUN THE GAMUT ACROSS A

688
00:24:11,520 --> 00:24:16,040
NUMBER OF CANCER TARGETS, THOUGH

689
00:24:16,040 --> 00:24:18,880
CERTAINLY A LARGE PERCENTAGE OF

690
00:24:18,880 --> 00:24:21,080
THEM HAVE FOCUSED ON HPV-RELATED

691
00:24:21,080 --> 00:24:22,800
DIAGNOSTICS, GIVEN OUR ABILITY

692
00:24:22,800 --> 00:24:23,600
TO ADDRESS CERVICAL CANCER AT

693
00:24:23,600 --> 00:24:26,400
THE POINT OF NEED.

694
00:24:26,400 --> 00:24:27,600
WE'VE ALSO HAD A NUMBER AND YOU

695
00:24:27,600 --> 00:24:29,960
WILL HEAR ABOUT 1 OF THEM,

696
00:24:29,960 --> 00:24:32,920
DIAGNOSTICS ASSOCIATED WITH HIV

697
00:24:32,920 --> 00:24:35,800
ASSOCIATED CANCERS, SOME TOOLS

698
00:24:35,800 --> 00:24:38,720
FOCUSED ON COLORECTAL CANCER

699
00:24:38,720 --> 00:24:39,840
SCREENING, ESOPHAGEAL CANCER,

700
00:24:39,840 --> 00:24:41,520
EARLY DETECTION AND WE HAD 1

701
00:24:41,520 --> 00:24:44,360
DIAGNOSTIC TOOL THAT WAS FOCUSED

702
00:24:44,360 --> 00:24:45,640
ON CML DIAGNOSTICS AND

703
00:24:45,640 --> 00:24:47,120
MONITORING BUT THAT WAS 1

704
00:24:47,120 --> 00:24:49,040
PARTICULARLY INTERESTING BECAUSE

705
00:24:49,040 --> 00:24:51,480
IT WAS SORT OF LOW COST DIGITAL

706
00:24:51,480 --> 00:24:52,920
PC R WHICH COULD BE USED FOR A

707
00:24:52,920 --> 00:24:54,240
LOT OF OTHER THINGS.

708
00:24:54,240 --> 00:24:55,720
SO LONG STORY SHORT, IT'S A WIDE

709
00:24:55,720 --> 00:24:57,040
SPREAD BUT I THINK THE KEY TAKE

710
00:24:57,040 --> 00:25:02,320
AWAY FOR THE ACTS PROGRAM PART

711
00:25:02,320 --> 00:25:03,680
OF THE REVIEW CRITERIA IS THAT

712
00:25:03,680 --> 00:25:06,600
THESE PROJECT VS TO FOCUS ON

713
00:25:06,600 --> 00:25:07,600
PREVENTIBLE OR TREATABLE CANCERS

714
00:25:07,600 --> 00:25:09,080
AT THE NEED OF SETTINGS WHERE

715
00:25:09,080 --> 00:25:10,280
THE INVESTIGATORS ARE WORKING.

716
00:25:10,280 --> 00:25:11,680
>> OKAY, THAT'S JUST WHAT I

717
00:25:11,680 --> 00:25:14,600
WANTED TO HEAR, THANK YOU

718
00:25:14,600 --> 00:25:16,320
DR. PEARLMAN NIF I'M NOT

719
00:25:16,320 --> 00:25:19,200
MISTAKEN, I THINK ON THE WEBSITE

720
00:25:19,200 --> 00:25:21,240
OF THE CENTER'S WEBSITE, THESE

721
00:25:21,240 --> 00:25:23,280
ARE LISTED.

722
00:25:23,280 --> 00:25:23,920
>> ABSOLUTELY.

723
00:25:23,920 --> 00:25:24,320
>> ABSOLUTELY.

724
00:25:24,320 --> 00:25:25,520
SO WE PUT EFFORT INTO GENERATING

725
00:25:25,520 --> 00:25:29,520
QUITE A LOT OF CONTENT ON THE

726
00:25:29,520 --> 00:25:30,720
AFFORDABLE CANCER TECHNOLOGIES

727
00:25:30,720 --> 00:25:31,480
WEBSITE AND I ENCOURAGE PEOPLE

728
00:25:31,480 --> 00:25:34,840
WHO ARE INTERESTED TO TAKE A

729
00:25:34,840 --> 00:25:37,240
LOOK. 

730
00:25:37,240 --> 00:25:39,400
>> THANK YOU.

731
00:25:39,400 --> 00:25:41,200
>> ANY OTHER COMMENTS?

732
00:25:41,200 --> 00:25:42,160
QUESTIONS?

733
00:25:42,160 --> 00:25:47,320
WELL I SEE DR.  SHARPLESS HAS

734
00:25:47,320 --> 00:25:51,040
JOINED US AND THIS IS A PERFECT

735
00:25:51,040 --> 00:25:55,760
TIME TO, NED SHARPLESS, TO MAKE

736
00:25:55,760 --> 00:26:03,520
A FEW COMMENTS BEFORE WE

737
00:26:03,520 --> 00:26:07,440
CONTINUE. 

738
00:26:07,440 --> 00:26:08,560
NED SHARPLESS?

739
00:26:08,560 --> 00:26:11,520
>> I THINK YOU ARE HAVING A MIC

740
00:26:11,520 --> 00:26:11,840
ISSUE?

741
00:26:11,840 --> 00:26:13,400
>> I THINK HE IS MUTED.

742
00:26:13,400 --> 00:26:15,520
CAN HE BE UNMUTED?

743
00:26:15,520 --> 00:26:16,320
NHOW ABOUT NOW?

744
00:26:16,320 --> 00:26:16,640
>> GREAT.

745
00:26:16,640 --> 00:26:18,240
DID YOU HEAR MY COMEBTS?

746
00:26:18,240 --> 00:26:18,880
>> SOMEBODY SAY SOMETHING, I

747
00:26:18,880 --> 00:26:20,240
HAVE TO MAKE SURE I CAN HEAR YOU

748
00:26:20,240 --> 00:26:20,760
NOW.

749
00:26:20,760 --> 00:26:21,520
>> NED SHARPLESS, THIS IS

750
00:26:21,520 --> 00:26:23,000
FRANCIS, CAN YOU HEAR ME.

751
00:26:23,000 --> 00:26:25,120
>> I CAN HEAR YOU GREAT.

752
00:26:25,120 --> 00:26:25,280
IN.

753
00:26:25,280 --> 00:26:26,640
>> OKAY GREAT.

754
00:26:26,640 --> 00:26:28,520
I SAID WELCOME AND COMING AT A

755
00:26:28,520 --> 00:26:29,720
PERFECT TIME.

756
00:26:29,720 --> 00:26:31,320
>> I'VE BEEN HAVING COMPUTER

757
00:26:31,320 --> 00:26:32,600
DRAMA ALL DAY TODAY, IT'S THE

758
00:26:32,600 --> 00:26:35,840
FIRST DAY BACK AT WORK AND THIS

759
00:26:35,840 --> 00:26:41,720
COMPUTER WAS TROUBLE WHILE I WAS

760
00:26:41,720 --> 00:26:42,800
GONE.

761
00:26:42,800 --> 00:26:43,320
>> NED CAN'T HEAR US.

762
00:26:43,320 --> 00:26:47,280
>> HE CAN BE THE HEAR YOU, SIR.

763
00:26:47,280 --> 00:26:53,280
>> HE'S GOING TO LOG OFF AND LOG

764
00:26:53,280 --> 00:26:53,800
BACK ON.

765
00:26:53,800 --> 00:26:54,920
>> I WILL INTRODUCE THE SPEAKERS

766
00:26:54,920 --> 00:26:59,600
AND THEN WE CAN HEAR FROM NED?

767
00:26:59,600 --> 00:27:05,520
>> OKAY, ALL RIGHT.

768
00:27:05,520 --> 00:27:05,800
>> PAUL?

769
00:27:05,800 --> 00:27:06,240
>> GREAT, THANKS.

770
00:27:06,240 --> 00:27:08,720
SO WE HAVE GUESTS HERE TODAY.

771
00:27:08,720 --> 00:27:11,320
IF WE COULD MAYBE BRING UP MY

772
00:27:11,320 --> 00:27:15,520
LAST SLIDE 1 MORE TIME WHOEVER'S

773
00:27:15,520 --> 00:27:15,880
PILOTING IT.

774
00:27:15,880 --> 00:27:22,080
SO TODAY WE HAVE DR. SAMIRI, WHO

775
00:27:22,080 --> 00:27:24,320
WILL PRESENTOT ACTS SUPPORTED

776
00:27:24,320 --> 00:27:26,520
PROJECT TITLED EARLY STAGE

777
00:27:26,520 --> 00:27:29,880
DIAGNOSIS OF SARCOMA IN LIMITED

778
00:27:29,880 --> 00:27:31,160
RESOURCE SETTING USING

779
00:27:31,160 --> 00:27:37,360
KS-DETECT, HE IS JOINED BY DAVID

780
00:27:37,360 --> 00:27:38,840
ERICKSON, SUBSEQUENTLY

781
00:27:38,840 --> 00:27:40,280
DR. HANNAH SIM ONDS WILL PRESENT

782
00:27:40,280 --> 00:27:43,560
ON A PLANNING ASSISTANT FOR

783
00:27:43,560 --> 00:27:45,080
RADIATION PLANNING IN LMICs

784
00:27:45,080 --> 00:27:49,800
AND SHE'S JOINED BY DR. LAWRENCE

785
00:27:49,800 --> 00:27:52,120
COURT AND BETH BEAGLE FROM

786
00:27:52,120 --> 00:27:52,840
STANFORD PERSPECTIVELY.

787
00:27:52,840 --> 00:27:54,160
WE WERE HOPING TO SAVE QUESTIONS

788
00:27:54,160 --> 00:27:54,720
AT THE END.

789
00:27:54,720 --> 00:27:56,760
SO WITH NO FURTHER ADO I WANT TO

790
00:27:56,760 --> 00:28:12,800
TURN IT OVER TO DR. SEMEERE.

791
00:28:12,800 --> 00:28:14,520
>> CAN YOU HEAR US?

792
00:28:14,520 --> 00:28:17,960
>> YES I CAN.

793
00:28:17,960 --> 00:28:18,320
>> WONDERFUL.

794
00:28:18,320 --> 00:28:22,160
>> GOOD MORNING TO YOU ALL.

795
00:28:22,160 --> 00:28:24,520
THANK TO YOU THE ORGANIZERS FOR

796
00:28:24,520 --> 00:28:26,840
GIVING ME THIS--AND THE TEAM

797
00:28:26,840 --> 00:28:30,600
WITH THIS OPPORTUNITY TO SHARE

798
00:28:30,600 --> 00:28:36,960
WHAT WE HAVE LEARNED FROM THIS

799
00:28:36,960 --> 00:28:38,920
CHALLENGE OF KAPOSI SARCOMA WITH

800
00:28:38,920 --> 00:28:40,960
MY COLLEAGUE DAVID ERICSON, JUST

801
00:28:40,960 --> 00:28:43,600
TO GET THIS STARTED, THOSE WHO

802
00:28:43,600 --> 00:28:46,320
ARE NOT FAMILIAR, KAPOSI SARCOMA

803
00:28:46,320 --> 00:28:48,000
IS A CANCER ENDOTHELIAL CELL AND

804
00:28:48,000 --> 00:28:50,000
IT AFFECTS MOSTLY THE SKIN,

805
00:28:50,000 --> 00:28:52,840
MUCUS MEMBRANES AND SOMETIMES

806
00:28:52,840 --> 00:28:55,040
DOES EXTEND TO THE LUNGS AND GI

807
00:28:55,040 --> 00:28:55,360
TRACT.

808
00:28:55,360 --> 00:28:59,120
IT IS CAUSED BY A VIRUS, IT'S

809
00:28:59,120 --> 00:29:11,840
ASSOCIATED VIRUS ALSO IMOAZ AS

810
00:29:11,840 --> 00:29:14,120
HERPES VIRUS 8, IT WAS IN THE

811
00:29:14,120 --> 00:29:18,320
U.S. AND ALSO IN SUB-SAHARAN

812
00:29:18,320 --> 00:29:20,280
AFRICA, BUT WHEN HIV EPIDEMIC IT

813
00:29:20,280 --> 00:29:22,720
WAS BROUGHT TO THE FORE, AND YOU

814
00:29:22,720 --> 00:29:27,240
KNOW BECAME PERMANENT AS 1 OF

815
00:29:27,240 --> 00:29:28,480
THE POST DIAGNOSIS OF HIV AND

816
00:29:28,480 --> 00:29:28,960
AIDS.

817
00:29:28,960 --> 00:29:31,800
AND AS YOU KNOW HIV/AIDS HAS

818
00:29:31,800 --> 00:29:33,320
BEEN TREATED WITH ANTIRETROVIRAL

819
00:29:33,320 --> 00:29:36,040
THERAPY SO WHERE WE ARE NOW OUR

820
00:29:36,040 --> 00:29:38,240
INTEREST IS GETTING PATIENTS

821
00:29:38,240 --> 00:29:39,960
IMMUNE SYSTEMS NORMALIZED AND

822
00:29:39,960 --> 00:29:42,200
SO, THE QUESTION IS WHAT'S THE

823
00:29:42,200 --> 00:29:45,240
CURRENCE OF THIS CANCER IN A

824
00:29:45,240 --> 00:29:45,720
NORMALIZED INDIVIDUAL.

825
00:29:45,720 --> 00:29:50,600
WE DID LOOK AT THIS, AND FOUND

826
00:29:50,600 --> 00:29:51,520
AN INCIDENCE OF 31 PER HUNDRED

827
00:29:51,520 --> 00:29:54,040
THOUSAND OF COURSE THAT NUMBER

828
00:29:54,040 --> 00:29:55,600
MEANS NOTHING UNTIL YOU PUT IT

829
00:29:55,600 --> 00:29:56,520
IN CONTEXT.

830
00:29:56,520 --> 00:29:59,120
BUT LOOKINGA THE VERY MOST

831
00:29:59,120 --> 00:30:00,880
COMMON CANCERS FOR LOW INCOME

832
00:30:00,880 --> 00:30:02,000
COUNTRIES, JUST DOWN THERE, CAN

833
00:30:02,000 --> 00:30:05,320
YOU SEE THAT WITH AN INDENSE OF

834
00:30:05,320 --> 00:30:07,320
31, PER HUNDRED THOUSAND AT THE

835
00:30:07,320 --> 00:30:12,040
VERY TOP, IT'S NOT SOMETHING WE

836
00:30:12,040 --> 00:30:14,920
CANNOT IGNORE AND ANOTHER IS THE

837
00:30:14,920 --> 00:30:15,280
MORTALITY.

838
00:30:15,280 --> 00:30:19,280
UP TO 40% OF OUR PATIENTS DIE

839
00:30:19,280 --> 00:30:21,160
WITHIN A MONTH OF DIAGNOSIS AND

840
00:30:21,160 --> 00:30:23,480
YOU CAN SEE THAT MOST OF THIS

841
00:30:23,480 --> 00:30:25,480
DEATH HAPPENS WITHINLET FIRST 3

842
00:30:25,480 --> 00:30:28,160
MONTHS OF DIAGNOSIS AND THIS IS

843
00:30:28,160 --> 00:30:34,400
WHAT WE HAVE DONE IN EAST

844
00:30:34,400 --> 00:30:36,280
AFRICA, DIAGNOSIS AS WOULD BE

845
00:30:36,280 --> 00:30:40,440
SOCIAL SETTING WE TAKE A BIOPSY,

846
00:30:40,440 --> 00:30:42,840
WITH PATHOLOGIC DIAGNOSIS THAT

847
00:30:42,840 --> 00:30:47,680
LOOKS FOR SPINDLE CELLS,

848
00:30:47,680 --> 00:30:51,400
INFLAMMATORY, AND ABNORMAL

849
00:30:51,400 --> 00:30:52,040
VASCULATURE AND [INDISCERNIBLE]

850
00:30:52,040 --> 00:30:55,920
WOULD GIVE US A TYPICAL

851
00:30:55,920 --> 00:30:57,640
DIAGNOSIS BUT IN THE SOURCE

852
00:30:57,640 --> 00:31:03,080
SETTING IN THE MEAN 2000S WHEN

853
00:31:03,080 --> 00:31:11,040
WE LOOKED AT KS, PATIENTS WOULD

854
00:31:11,040 --> 00:31:13,200
GET A BIOPSY BUT THIS TIME NOT

855
00:31:13,200 --> 00:31:16,560
WITH A BUNCH BUT A WEDGE BIOPSY.

856
00:31:16,560 --> 00:31:19,280
THOSE SURGEONS KNOW HA THAT THIS

857
00:31:19,280 --> 00:31:22,040
IS A HERCULEAN TASK TO ORGANIZE

858
00:31:22,040 --> 00:31:24,120
AND THAT MEANS THAT BIOPSY WAS

859
00:31:24,120 --> 00:31:25,280
RARE.

860
00:31:25,280 --> 00:31:28,320
LOOKING AT DATA FROM ZIMBABWE,

861
00:31:28,320 --> 00:31:32,480
WE SAW FROM A STUDY THAT ONLY

862
00:31:32,480 --> 00:31:33,640
23% OF 700 DIAGNOSIS WERE

863
00:31:33,640 --> 00:31:37,120
POSITIVELY CONFIRMED AND IN OUR

864
00:31:37,120 --> 00:31:41,160
WORK, JUST SHOWING 36% OUT OF

865
00:31:41,160 --> 00:31:44,520
OVER 2439 VIRUSES PATH-CONFIRMED

866
00:31:44,520 --> 00:31:47,720
BUT WITH GRAFTS THERE WAS A

867
00:31:47,720 --> 00:31:50,720
TENDENCY IN THE COMMENTS AND OF

868
00:31:50,720 --> 00:31:51,400
COURSE, THAT PATHOLOGY IS

869
00:31:51,400 --> 00:31:54,480
IMPORTANT IF SOMEONE IS TO GET

870
00:31:54,480 --> 00:31:54,760
TREATED.

871
00:31:54,760 --> 00:31:57,720
BUT IF YOU CAN'T GET IT, WHAT

872
00:31:57,720 --> 00:31:58,160
THEN HAPPENS?

873
00:31:58,160 --> 00:32:00,120
SO TO TRY AND GET AROUND THIS

874
00:32:00,120 --> 00:32:05,800
TOGETHER WITH SOME NIH FUNDING

875
00:32:05,800 --> 00:32:08,520
AND WE THREW THE EAST AFRICA

876
00:32:08,520 --> 00:32:10,920
IDEA, NCI DID HELP US START A

877
00:32:10,920 --> 00:32:20,520
BIOPSY SERVICE WHERE WE TRAIN

878
00:32:20,520 --> 00:32:25,320
[AUDIO CUTS OUT ]

879
00:32:25,320 --> 00:32:29,200
THOUSAND 7 AND WITH THIS BIOPSY

880
00:32:29,200 --> 00:32:31,200
COMING THROUGH ABOUT BUT THAT

881
00:32:31,200 --> 00:32:32,720
WILL BE--WE HAD CHALLENGES WITH

882
00:32:32,720 --> 00:32:34,720
TURN AROUND TIME AND AT 1 MONTH,

883
00:32:34,720 --> 00:32:37,960
YOU KNOW ABOUT A THIRD OF OUR

884
00:32:37,960 --> 00:32:39,360
PATIENTS, A THIRD OF OUR RESULTS

885
00:32:39,360 --> 00:32:40,480
WERE NOT YET RETURNED TO THE

886
00:32:40,480 --> 00:32:48,600
PATIENT AND YOU CAN SEE IN THIS

887
00:32:48,600 --> 00:32:49,600
GRAPH THAT SOME OF THEM DIE

888
00:32:49,600 --> 00:32:55,280
WITHIN A FEW WEEKS OF BIOPSY.

889
00:32:55,280 --> 00:32:57,960
AND SO, THERE IS THE FACT THAT

890
00:32:57,960 --> 00:32:59,360
WE HAD ACCURACY CHALLENGES.

891
00:32:59,360 --> 00:33:02,440
WE DID COMPARE THE PATHOLOGY

892
00:33:02,440 --> 00:33:03,720
READS FROM UGANDA AND KENYA TO

893
00:33:03,720 --> 00:33:07,000
THOSE THAT 1 WOULD GET FROM THE

894
00:33:07,000 --> 00:33:13,800
U.S. PATHOLOGIST AND WAS ONLY

895
00:33:13,800 --> 00:33:15,200
[INDISCERNIBLE] IN 70% COMPARED

896
00:33:15,200 --> 00:33:15,560
THIS.

897
00:33:15,560 --> 00:33:16,640
SO THIS PICTURE NEEDED

898
00:33:16,640 --> 00:33:17,920
SOMETHING, A BETTER WAY, AN

899
00:33:17,920 --> 00:33:19,720
OPTION FOR US TO LOOK AT THIS.

900
00:33:19,720 --> 00:33:25,760
SO WE WENT BACK TO THE CENTRAL

901
00:33:25,760 --> 00:33:27,520
MARK THAT'S VIRUS IS A NECESSARY

902
00:33:27,520 --> 00:33:32,480
CAUSE OF AGENT AND THIS IF WE

903
00:33:32,480 --> 00:33:33,200
COULD USE THIS APPROACH, IT

904
00:33:33,200 --> 00:33:35,560
WOULD HAVE AN IDEA OF TIMING

905
00:33:35,560 --> 00:33:38,280
THIS INTO A LIQUID BIOPSY AND

906
00:33:38,280 --> 00:33:40,600
EVEN AN INITIAL POINT OF CARE

907
00:33:40,600 --> 00:33:45,800
PROCESS THAT REDUCES THE TIME TO

908
00:33:45,800 --> 00:33:47,120
DIAGNOSIS, BUT IT CHALLENGE IS

909
00:33:47,120 --> 00:33:56,400
THAT UP TO OVER 80% OF ADULTS IN

910
00:33:56,400 --> 00:33:58,480
SUB-SAHARAN AFRICA ARE

911
00:33:58,480 --> 00:34:01,440
KSHV-POSITIVE, AND SO SOMETHING

912
00:34:01,440 --> 00:34:04,440
LIKE THIS, THE BIOPSY, COULD NOT

913
00:34:04,440 --> 00:34:05,160
BE SPECIFIC.

914
00:34:05,160 --> 00:34:06,120
SO THIS NEEDED TESTING.

915
00:34:06,120 --> 00:34:09,800
AND WE JOINED EFFORTS WITH THE

916
00:34:09,800 --> 00:34:12,000
TEAM AT CORNELL WHO WERE

917
00:34:12,000 --> 00:34:16,800
ACTUALLY TESTING SOME PROTOTYPES

918
00:34:16,800 --> 00:34:18,040
IN 2014, THEY BROUGHT THIS RED

919
00:34:18,040 --> 00:34:20,720
BOX WE CALL IT, IT JUST USED

920
00:34:20,720 --> 00:34:25,520
SOLAR AND WITH FEEDBACK WE

921
00:34:25,520 --> 00:34:26,520
LOOKED AT [INDISCERNIBLE] AND

922
00:34:26,520 --> 00:34:27,680
GIVE THEM FEEDBACK AND SHOWED

923
00:34:27,680 --> 00:34:28,720
THEM WHERE THE CHALLENGES WERE

924
00:34:28,720 --> 00:34:31,640
AND THEN THEY CAME UP WITH THE

925
00:34:31,640 --> 00:34:36,120
BLACK BOX, THE BLACK BOX [AUDIO

926
00:34:36,120 --> 00:34:37,920
CUTS OUT ] BUT STILL THERE WERE

927
00:34:37,920 --> 00:34:39,920
ISSUES AND THINK IT COULDN'T BE

928
00:34:39,920 --> 00:34:42,240
USED IN CERTAIN SETTING AND

929
00:34:42,240 --> 00:34:44,000
FINALLY WE HAVE THE WHITE BOX

930
00:34:44,000 --> 00:34:45,240
WHICH IS EVEN SMALLER AND THIS

931
00:34:45,240 --> 00:34:51,600
IS NOW WHAT WE CALL THE TIEN O

932
00:34:51,600 --> 00:34:52,880
ISOTHERMONUCLEOTIDES CLITIC

933
00:34:52,880 --> 00:34:57,680
SYSTEM, IT CAN DO 6 TESTS, THAT

934
00:34:57,680 --> 00:34:59,040
6 TIMES MULTIPLEXING AND

935
00:34:59,040 --> 00:35:00,040
OPERATES ON BOTH ELECTRIC,

936
00:35:00,040 --> 00:35:03,400
BATTERY AND SOLAR AND USES PHASE

937
00:35:03,400 --> 00:35:07,600
CHANGE MEDIA TO MAINTAIN

938
00:35:07,600 --> 00:35:08,080
CONSTANT TEMPERATURE.

939
00:35:08,080 --> 00:35:11,320
AND BUILDING ON OUR PREVIOUS

940
00:35:11,320 --> 00:35:12,480
PREBIOPSY PLATFORM, ALL WE

941
00:35:12,480 --> 00:35:15,080
NEEDED TO DO NOW IS INSTEAD OF

942
00:35:15,080 --> 00:35:20,320
JUST DOING 1 BIOPSY  DISSECT IT

943
00:35:20,320 --> 00:35:22,920
AND THEN 1 PART GOES TO THE

944
00:35:22,920 --> 00:35:25,040
TYPICAL PATHWAY WHICH INFORMS

945
00:35:25,040 --> 00:35:29,240
CLEAR, BUT THEN THERE IS--FOR

946
00:35:29,240 --> 00:35:31,640
THE GOLD STANDARD TESTING, THEN

947
00:35:31,640 --> 00:35:34,720
THE OTHER HALF GOES THROUGH THE

948
00:35:34,720 --> 00:35:35,520
QUANTIFICATION OF NUCLEIC ACID

949
00:35:35,520 --> 00:35:37,120
AND THIS WAS INITIALLY HAPPENING

950
00:35:37,120 --> 00:35:44,320
AT CORNELL WHERE WE WOULD

951
00:35:44,320 --> 00:35:49,320
EXTRACT DNA USING A QIAGEN KIT

952
00:35:49,320 --> 00:35:49,720
AND RUNNING IT.

953
00:35:49,720 --> 00:35:51,240
WHAT DID WE LEARN?

954
00:35:51,240 --> 00:35:52,920
WE DID GET SENSITIVITY SO WHEN

955
00:35:52,920 --> 00:35:57,680
WE COMPARE GOLD STANDARD

956
00:35:57,680 --> 00:35:59,360
HISTOPATHOLOGY TO THE LAMP FOR

957
00:35:59,360 --> 00:36:02,720
TIMING OF 500 PATIENTS WE GOT A

958
00:36:02,720 --> 00:36:10,320
SPEC SPISSITY OF 93% AND A

959
00:36:10,320 --> 00:36:18,520
SPECIFICITY OF 94% AND WE HAD A

960
00:36:18,520 --> 00:36:22,200
WAY TO CLASSIFY ALMOST 96, WHERE

961
00:36:22,200 --> 00:36:24,360
WE ARE, WE AGAIN ARE GOING BACK

962
00:36:24,360 --> 00:36:28,200
AND BUILT ON TO AN NIH FUNDED

963
00:36:28,200 --> 00:36:32,040
MECHANISM, THE U54 NETWORK TO

964
00:36:32,040 --> 00:36:34,840
GET 9 CLINICAL SITES IN 6

965
00:36:34,840 --> 00:36:37,200
COUNTRIES AND THIS IS IN UGANDA

966
00:36:37,200 --> 00:36:39,880
WHERE WE'RE COORDINATING THIS

967
00:36:39,880 --> 00:36:42,240
AND THAT'S WHERE WE INVEST IN

968
00:36:42,240 --> 00:36:48,200
RWANDA, AGAIN IN KENYA,

969
00:36:48,200 --> 00:36:49,960
TANZANIA, MALAWI, AND IN THIS

970
00:36:49,960 --> 00:36:52,240
SITE WE ARE ACTIVELY ENROLLING

971
00:36:52,240 --> 00:36:55,080
THROUGH HELP US VALIDATE THE

972
00:36:55,080 --> 00:36:57,920
CURRENT DEVICE, SO SO FAR WE'VE

973
00:36:57,920 --> 00:37:00,120
ENROLLED UP TO 700 PATIENTS OUT

974
00:37:00,120 --> 00:37:00,320
OF 820.

975
00:37:00,320 --> 00:37:02,520
OF COURSE THIS HAS BEEN SLOWED

976
00:37:02,520 --> 00:37:03,720
DOWN OVER THE LAST 2 YEARS

977
00:37:03,720 --> 00:37:07,720
BECAUSE OF WHAT EVERYBODY KNOWS,

978
00:37:07,720 --> 00:37:11,120
THE COVID CHALLENGES BUT WE TILL

979
00:37:11,120 --> 00:37:12,400
PROGRESS TO VALIDATE THIS AND TO

980
00:37:12,400 --> 00:37:14,720
SHOW YOU HOW THE

981
00:37:14,720 --> 00:37:15,720
MULTIDISCIPLINARY APPROACH THAT

982
00:37:15,720 --> 00:37:21,440
WE REALLY NEEDED, WE NEEDED THE

983
00:37:21,440 --> 00:37:23,000
ENGINEERS, DERMATOLOGISTS,

984
00:37:23,000 --> 00:37:24,040
PATHOLOGISTS AND LARGE

985
00:37:24,040 --> 00:37:26,520
EPIDEMIOLOGISTS, CLINICAL AND

986
00:37:26,520 --> 00:37:28,640
CLINICIANS ACROSS DIFFERENT

987
00:37:28,640 --> 00:37:29,880
PLACES AND DIFFERENT SITES TO

988
00:37:29,880 --> 00:37:33,400
PULL THIS OFF.

989
00:37:33,400 --> 00:37:37,720
SO, I WOULD BE ABLE TO--YOU KNOW

990
00:37:37,720 --> 00:37:41,520
PRIOR LARGELY WE WERE--WITH THE

991
00:37:41,520 --> 00:37:45,120
DIAGNOSIS FOR THAT CASE IN

992
00:37:45,120 --> 00:37:48,240
SUB-SAHARAN AFRICA AND PATHOLOGY

993
00:37:48,240 --> 00:37:49,760
DID PERFORM TURN AROUND AND

994
00:37:49,760 --> 00:37:53,760
ACCURACY, BUT THIS QUANTITATIVE

995
00:37:53,760 --> 00:37:56,920
OF CARE KSHV DNA DOES OFFER

996
00:37:56,920 --> 00:37:58,640
PROMISE BECAUSE WE DEMONSTRATED

997
00:37:58,640 --> 00:37:59,400
SENSITIVITY AND SPECIFICITY BUT

998
00:37:59,400 --> 00:38:03,960
NOW WE NEED TO VALIDATE IT

999
00:38:03,960 --> 00:38:05,680
ROBUSTLY AND THIS SUDDENLY WILL

1000
00:38:05,680 --> 00:38:06,680
BE RELEVANT FOR RESEARCH SETTING

1001
00:38:06,680 --> 00:38:07,000
AS WELL.

1002
00:38:07,000 --> 00:38:10,080
AND I THINK WE ENVISION A FUTURE

1003
00:38:10,080 --> 00:38:12,720
WHERE WE CAN HAVE AUTOMATED

1004
00:38:12,720 --> 00:38:14,920
MOLECULAR DIAGNOSIS FOR CARES AS

1005
00:38:14,920 --> 00:38:16,320
A STANDARD OPERATION IN ANY

1006
00:38:16,320 --> 00:38:16,560
SETTING.

1007
00:38:16,560 --> 00:38:23,240
THANK YOU VERY MUCH.

1008
00:38:23,240 --> 00:38:25,120
>> WONDERFUL.

1009
00:38:25,120 --> 00:38:26,160
THANK YOU.

1010
00:38:26,160 --> 00:38:27,920
PAUL, YOU INTRODUCED DR. SIMMONS

1011
00:38:27,920 --> 00:38:28,080
NOW.

1012
00:38:28,080 --> 00:38:28,440
>> YES, SIR.

1013
00:38:28,440 --> 00:38:29,720
>> IF YOU WANT TO DO BOTH AND GO

1014
00:38:29,720 --> 00:38:30,760
TO THE QUESTIONS, RIGHT?

1015
00:38:30,760 --> 00:38:32,720
>> YEAH, I THINK THAT WAY WE CAN

1016
00:38:32,720 --> 00:38:34,320
INCLUDE ALL OF THE OTHER GUESTS

1017
00:38:34,320 --> 00:38:35,040
AS WELL.

1018
00:38:35,040 --> 00:38:39,320
SO OUR NEXT TALK WILL BE FROM

1019
00:38:39,320 --> 00:38:41,040
DR. SIMMONS FROM [INDISCERNIBLE]

1020
00:38:41,040 --> 00:38:42,360
UNIVERSITY. 

1021
00:38:42,360 --> 00:38:43,120
DR. SIMMONS?

1022
00:38:43,120 --> 00:38:47,880
>> GOOD EVENING, EVERYBODY FROM

1023
00:38:47,880 --> 00:38:48,200
SOUTH AFRICA.

1024
00:38:48,200 --> 00:38:49,040
THANK YOU VERY MUCH FROM THE

1025
00:38:49,040 --> 00:38:51,080
ADVISORY BOARD TO TALK TO YOU

1026
00:38:51,080 --> 00:38:52,040
TODAY.

1027
00:38:52,040 --> 00:38:54,160
OUR PROJECT IS THE RADIATION

1028
00:38:54,160 --> 00:38:54,920
PLANNING ASSISTANT, I'M JUST

1029
00:38:54,920 --> 00:38:56,720
WAITING IF ARE MY SLIDES, AND

1030
00:38:56,720 --> 00:38:59,920
THIS IS AN AUTOMATED RADIATION

1031
00:38:59,920 --> 00:39:01,800
PLANNING TECHNOLOGY, THAT'S BEEN

1032
00:39:01,800 --> 00:39:04,280
DEVELOPED FOR LOW AND MIDDLE

1033
00:39:04,280 --> 00:39:08,520
INCOME COUNTRIES AND IS THE

1034
00:39:08,520 --> 00:39:11,480
BRAIN CHILD OF DR. COURT AND

1035
00:39:11,480 --> 00:39:12,800
DR. BEAGLE.

1036
00:39:12,800 --> 00:39:14,160
NEXT SLIDE, PLEASE.

1037
00:39:14,160 --> 00:39:15,760
SO RADIATION RESOURCES IN AFRICA

1038
00:39:15,760 --> 00:39:20,480
IS A REAL CHALLENGE, AS OF

1039
00:39:20,480 --> 00:39:22,320
MARCH 2020 OR 50% OF AFRICAN

1040
00:39:22,320 --> 00:39:24,080
COUNTRIES HAD ACCESS AND LESS

1041
00:39:24,080 --> 00:39:26,040
THAN 40% HAVE ACCESS TO BREAKY

1042
00:39:26,040 --> 00:39:28,320
THERAPY WHICH IS CRITICAL TO

1043
00:39:28,320 --> 00:39:29,960
SURVIVAL CANCER AND NO COUNTRY

1044
00:39:29,960 --> 00:39:33,120
IN AFRICA HAS THE CAPACITY TO

1045
00:39:33,120 --> 00:39:34,600
MEET THE ESTIMATED NEED,

1046
00:39:34,600 --> 00:39:36,440
ACCEPTABLE PRACTICE ESTABLISHED

1047
00:39:36,440 --> 00:39:38,280
BY THE IAAIS 1 MACHINE PER

1048
00:39:38,280 --> 00:39:39,600
250,000 POPULATION AND NOT A

1049
00:39:39,600 --> 00:39:43,120
SINGLE POPULATION IN AFRICA CAN

1050
00:39:43,120 --> 00:39:43,920
ACHIEVE THIS.

1051
00:39:43,920 --> 00:39:45,600
AND THIRD 50% OF ALL RESOURCES

1052
00:39:45,600 --> 00:39:47,080
ARE ISOLATED IN THE NORTH AND

1053
00:39:47,080 --> 00:39:48,320
SOUTH OF AFRICA AND CENTRAL

1054
00:39:48,320 --> 00:39:53,120
AFRICA IS VERY MUCH IN NEED. 

1055
00:39:53,120 --> 00:39:53,960
NEXT SLIDE, PLEASE.

1056
00:39:53,960 --> 00:39:55,200
BUT HARDWARE IS NOT ALL THE

1057
00:39:55,200 --> 00:39:55,520
PROBLEM.

1058
00:39:55,520 --> 00:39:58,320
WE HAVE A BIG ISSUE WITH TRAINED

1059
00:39:58,320 --> 00:39:59,040
PERSONNEL SO CLINICAL ONCOLOGY

1060
00:39:59,040 --> 00:40:01,000
SHOT FULL IS A WORLD WIDE ISSUE

1061
00:40:01,000 --> 00:40:02,920
WITH 8 COUNTRIES IN THE WORLD

1062
00:40:02,920 --> 00:40:04,320
HAVING NO CLINICAL ONCOLOGIST AT

1063
00:40:04,320 --> 00:40:07,520
ALL AND MOST OF THOSE COUNTRIES

1064
00:40:07,520 --> 00:40:09,920
IN AFRICA, 27 COUNTRY VS A

1065
00:40:09,920 --> 00:40:18,440
CLINICAL ONCOLOGIST ONLY FOR 1

1066
00:40:18,440 --> 00:40:19,320
ONCOLOGIST FOR EVERY 23,000

1067
00:40:19,320 --> 00:40:22,880
CASES BUT NOT ONLY DO WE HAVE A

1068
00:40:22,880 --> 00:40:23,520
SHORTAGE OF MEDICAL ONCOLOGISTS

1069
00:40:23,520 --> 00:40:27,520
BUT WE HAVE A SHORTAGE OF

1070
00:40:27,520 --> 00:40:28,600
RADIATION SPECIALISTS AND

1071
00:40:28,600 --> 00:40:29,760
MEDICAL SPECIALISTS SO IN MY

1072
00:40:29,760 --> 00:40:31,640
SECTOR I HAVE TO SIGN OFF AND

1073
00:40:31,640 --> 00:40:36,720
PLAN FOR MORE THAN 400 PLANS A

1074
00:40:36,720 --> 00:40:38,480
YEAR BUT MY COLLEAGUES HAVE TO

1075
00:40:38,480 --> 00:40:40,280
DO 2000 CASES A YEAR.

1076
00:40:40,280 --> 00:40:41,320
NEXT SLIDE, PLEASE.

1077
00:40:41,320 --> 00:40:42,880
SO RADIO THERAPY IS COMPLEX ON

1078
00:40:42,880 --> 00:40:44,800
MANY LEVELS, NOT ONLY FROM A

1079
00:40:44,800 --> 00:40:46,200
TECHNOLOGY AND A HARDWARE POINT

1080
00:40:46,200 --> 00:40:48,440
OF VIEW BUT NEEDS MULTIPLE

1081
00:40:48,440 --> 00:40:51,960
TRAINED PERSONNEL.

1082
00:40:51,960 --> 00:40:53,280
NEXT SLIDE.

1083
00:40:53,280 --> 00:40:54,840
AND SO THERE'S GREAT POTENTIAL

1084
00:40:54,840 --> 00:40:56,360
FOR AUTOMATION IN ALL OF THESE

1085
00:40:56,360 --> 00:40:58,360
STEPS.

1086
00:40:58,360 --> 00:40:59,000
NEXT SLIDE, PLEASE.

1087
00:40:59,000 --> 00:41:02,120
AND WHAT HAS BEEN FOUND IS THAT

1088
00:41:02,120 --> 00:41:04,920
NEARLY 60-70% OF ALL RADIATION

1089
00:41:04,920 --> 00:41:07,040
PROCESSES COULD BE USED,

1090
00:41:07,040 --> 00:41:09,000
AUTOMATED AND AI COULD BE USED,

1091
00:41:09,000 --> 00:41:12,200
FIRST OF ALL AUTOMATED, AND

1092
00:41:12,200 --> 00:41:14,240
PLANNING TASKS FOR THE M. D. AND

1093
00:41:14,240 --> 00:41:15,960
THEN TO PRODUCE HIGH QUALITY

1094
00:41:15,960 --> 00:41:17,360
PLANS AND CONTROLS WHICH

1095
00:41:17,360 --> 00:41:20,480
INCREASES CONSISTENCY AND

1096
00:41:20,480 --> 00:41:32,680
REDUCED EDITS AND

1097
00:41:32,680 --> 00:41:33,600
[INDISCERNIBLE] SO THE POETIC

1098
00:41:33,600 --> 00:41:36,320
TEBTIAL IMPACT FOR US IN THE

1099
00:41:36,320 --> 00:41:39,200
LMICs IT COULD ASSIST IN THIS

1100
00:41:39,200 --> 00:41:39,760
HUGE OVERWHELMING WORKFORCE

1101
00:41:39,760 --> 00:41:41,440
CHALLENGE THAT WE HAVE, THEREBY

1102
00:41:41,440 --> 00:41:44,840
REDUCING TASKS FOR ALL INVOLVED.

1103
00:41:44,840 --> 00:41:46,240
IT COULD ALSO REDUCE OBSERVE

1104
00:41:46,240 --> 00:41:48,240
VARIABILITY BECAUSE THE SKILLS

1105
00:41:48,240 --> 00:41:50,240
MIXED ACROSS THE CONTINENT IS

1106
00:41:50,240 --> 00:41:52,120
QUITE VARIABLE AND THE RPA HAS

1107
00:41:52,120 --> 00:41:53,200
THE POTENTIAL TO ASSIST SKILLS

1108
00:41:53,200 --> 00:41:55,840
IN NEW OR LIMITED AND WHETHER

1109
00:41:55,840 --> 00:41:56,760
THEY'RE JUNIOR, STAFF ARE IN

1110
00:41:56,760 --> 00:41:58,640
CHARGE OF THE DEPARTMENTS AND IT

1111
00:41:58,640 --> 00:42:00,040
CAN ALSO AND MOST IMPORTANTLY

1112
00:42:00,040 --> 00:42:02,520
INCREASE SAFETY BY REDUCTION OF

1113
00:42:02,520 --> 00:42:04,040
HUMAN ERROR OPPORTUNITIES.

1114
00:42:04,040 --> 00:42:07,080
THE CHALLENGE IS FOR ALL OF US,

1115
00:42:07,080 --> 00:42:08,560
OUR STAFF, RESPONSES, MY OWN

1116
00:42:08,560 --> 00:42:10,880
STAFF HAVE CONCERNED ABOUT

1117
00:42:10,880 --> 00:42:12,280
FEELINGS OF THEIR OWN VALUE,

1118
00:42:12,280 --> 00:42:14,240
LACK OF RECOGNITION OF THEIR OWN

1119
00:42:14,240 --> 00:42:15,440
EXPERTISE AND WITH ALL OF US WE

1120
00:42:15,440 --> 00:42:18,000
HAVE A FEAR OF THE UNKNOWN AND

1121
00:42:18,000 --> 00:42:22,160
POTENTIALLY COULD REDUCE

1122
00:42:22,160 --> 00:42:23,960
OPPORTUNITY FOR TRAINING FOR

1123
00:42:23,960 --> 00:42:25,720
RADIOLOGY STUDENTS AND ONCOLOGY

1124
00:42:25,720 --> 00:42:27,720
AND THE RESOURCE REQUIREMENTS

1125
00:42:27,720 --> 00:42:28,440
ARE SIGNIFICANT.

1126
00:42:28,440 --> 00:42:30,760
IT REQUIRES CT PLANNING

1127
00:42:30,760 --> 00:42:32,520
HARDWARE, MANY CENTERS CT

1128
00:42:32,520 --> 00:42:37,400
SCANNERS ARE OFFSITE, WE NEED

1129
00:42:37,400 --> 00:42:39,280
SOFTWARE CAPABILITIES AND 3D

1130
00:42:39,280 --> 00:42:41,720
IMAGES, HERE, ASK REQUIRES I.T.

1131
00:42:41,720 --> 00:42:43,040
INFRASTRUCTURE, SUPPORT AND

1132
00:42:43,040 --> 00:42:44,760
SERVICE AND THE 1 THING WE DO

1133
00:42:44,760 --> 00:42:47,080
KNOW IN AFRICA WE STRUGGLE TO

1134
00:42:47,080 --> 00:42:48,040
ACHIEVE STABLE INTERNET AND OF

1135
00:42:48,040 --> 00:42:54,280
COURSE THE BIG FACTOR IS COST. 

1136
00:42:54,280 --> 00:42:55,160
NEXT SLIDE, PLEASE.

1137
00:42:55,160 --> 00:42:58,600
>> SO THE RPA GOALS ARE REALLY

1138
00:42:58,600 --> 00:43:00,240
DESIGNED FOR SCALABILITY, WEB OF

1139
00:43:00,240 --> 00:43:00,920
HAD BASED SOLUTIONS HAVE BEEN

1140
00:43:00,920 --> 00:43:02,520
WORKED ON AND THE MAIN BENEFIT

1141
00:43:02,520 --> 00:43:05,120
OF A WEB BASED SOLUTION IS EASY

1142
00:43:05,120 --> 00:43:06,080
UPGREAT AND PROMOTE MAINTENANCE

1143
00:43:06,080 --> 00:43:08,520
AND ALSO THE HUGE CAPACITY TO

1144
00:43:08,520 --> 00:43:09,800
PLAN MORE THAN A HUNDRED

1145
00:43:09,800 --> 00:43:15,080
THOUSAND PATIENTS PER YEAR. 

1146
00:43:15,080 --> 00:43:15,880
NEXT SLIDE, PLEASE.

1147
00:43:15,880 --> 00:43:17,520
>> SO THE RPA IS BEING DEVELOPED

1148
00:43:17,520 --> 00:43:19,520
WITH THE ABILITY TO DO MULTIPLE

1149
00:43:19,520 --> 00:43:21,160
TASKS, FIRSTLY THE ABILITY TO

1150
00:43:21,160 --> 00:43:22,200
ORDER CONTROL, NORMAL TISSUES

1151
00:43:22,200 --> 00:43:28,080
AND TARGETS IS NOW COMPLETE.

1152
00:43:28,080 --> 00:43:29,200
NEXT SLIDE.

1153
00:43:29,200 --> 00:43:30,120
ABILITY TO AUTOMATICALLY

1154
00:43:30,120 --> 00:43:31,320
GENERATE HIGH QUALITY RATED

1155
00:43:31,320 --> 00:43:32,440
THERAPY PLAN SYSTEM WELL ON THE

1156
00:43:32,440 --> 00:43:34,440
WAY TO BEING COMPLETE.

1157
00:43:34,440 --> 00:43:35,600
SIMPLE PLANS OF 2 D RADIO

1158
00:43:35,600 --> 00:43:37,120
THERAPY WHICH CAN BE USED IN

1159
00:43:37,120 --> 00:43:38,960
MANY CENTERS IN AFFRIC A3D RATED

1160
00:43:38,960 --> 00:43:41,000
THERAPY WHICH CAN BE USED IN

1161
00:43:41,000 --> 00:43:42,600
SOME AND THOSE OF US THAT ARE

1162
00:43:42,600 --> 00:43:47,120
LUCKY TO HAVE HIGH-TECHNOLOGY

1163
00:43:47,120 --> 00:43:48,680
WITH ROTATIONAL THERAPY, IT HAS

1164
00:43:48,680 --> 00:43:52,120
THE ABILITY TO GENERATE VMAT

1165
00:43:52,120 --> 00:43:53,560
PLANS.

1166
00:43:53,560 --> 00:43:54,280
NEXT SLIDE, PLEASE.

1167
00:43:54,280 --> 00:43:56,040
AND MOST IMPORTANTLY AS WE

1168
00:43:56,040 --> 00:43:57,920
DISCUSSED IT CAN AUTOMATICALLY

1169
00:43:57,920 --> 00:43:59,720
ASSURE QUALITY AND IDENTIFY

1170
00:43:59,720 --> 00:44:01,720
POTENTIAL FAILURES.

1171
00:44:01,720 --> 00:44:02,760
BECAUSE QUALITY INTERPERENSEL OF

1172
00:44:02,760 --> 00:44:04,320
BOTH CONTROLS AND PLANS IS

1173
00:44:04,320 --> 00:44:05,920
ESSENTIAL FOR PATIENT SAFETY AND

1174
00:44:05,920 --> 00:44:08,360
ALL AUTOMATED TASKS ARE REPEATED

1175
00:44:08,360 --> 00:44:10,720
WITH AN INDEPENDENT ALGORITHM IN

1176
00:44:10,720 --> 00:44:12,920
THE RPA AND OUTLIES A FLAG FOR

1177
00:44:12,920 --> 00:44:13,680
THE USER AND EACH IMPORTANT STEP

1178
00:44:13,680 --> 00:44:14,960
OF THE WAY, IT WILL BE SIGNED

1179
00:44:14,960 --> 00:44:19,920
OFF BY A CLINICIAN.

1180
00:44:19,920 --> 00:44:20,960
NEXT SLIDE, PLEASE.

1181
00:44:20,960 --> 00:44:22,960
SO THE CURRENT STATUS OF THE RPA

1182
00:44:22,960 --> 00:44:25,600
IS DEVELOPED FOR MULTIPLE CANCER

1183
00:44:25,600 --> 00:44:27,000
SITES, NOVEL APPROACHES 

1184
00:44:27,000 --> 00:44:27,840
AND DIFFERENT

1185
00:44:27,840 --> 00:44:28,880
PARADIGMS, IT'S BEEN DEVELOPED

1186
00:44:28,880 --> 00:44:31,240
WITH SOLUTIONS BASED ON LOCAL

1187
00:44:31,240 --> 00:44:33,200
PRACTICE FROM DIFFERENT LMIC

1188
00:44:33,200 --> 00:44:35,880
CENTERS, OUR OWN PATIENTS OFTEN

1189
00:44:35,880 --> 00:44:37,680
HAVE ADVANCED LARGE TUMORS AND

1190
00:44:37,680 --> 00:44:40,080
CLINICAL TEAMS AND SKILLS AND

1191
00:44:40,080 --> 00:44:40,280
NEEDS.

1192
00:44:40,280 --> 00:44:42,680
IT'S GONE THROUGH COMPREHENSIVE

1193
00:44:42,680 --> 00:44:43,880
CLINICAL ACCEPTABILITY TESTING,

1194
00:44:43,880 --> 00:44:49,800
31 RADIATION ONCOLOGISTS, TEN 

1195
00:44:49,800 --> 00:44:52,760
INSTITUTIONS, 75 PATIENTS PER

1196
00:44:52,760 --> 00:44:54,960
SITE, OVER 8,000 RATINGS.

1197
00:44:54,960 --> 00:44:56,560
THIS INCLUSION OF THOSE RATINGS

1198
00:44:56,560 --> 00:45:05,440
OVERALL BETWEEN 90 AND 100% OF

1199
00:45:05,440 --> 00:45:06,560
RGA GENERATED TUMORS AND

1200
00:45:06,560 --> 00:45:10,880
CONTOURS USED WITH NO EDITS, OR

1201
00:45:10,880 --> 00:45:13,440
SOME MINOR EDITS WHICH MAKE TAKE

1202
00:45:13,440 --> 00:45:14,680
TEN MINUTES.

1203
00:45:14,680 --> 00:45:17,560
THE OTHER IS THE RESEARCH

1204
00:45:17,560 --> 00:45:18,720
OUTPUTS, VERY SUCCESSFUL

1205
00:45:18,720 --> 00:45:25,720
DIRECTLY FROM THE UH2 AND UH3

1206
00:45:25,720 --> 00:45:29,440
OUTPUT, TEN PAPERS IN HIGH

1207
00:45:29,440 --> 00:45:30,360
QUALITY JOURNALS, FIFTEEN

1208
00:45:30,360 --> 00:45:30,840
PAPERS.

1209
00:45:30,840 --> 00:45:32,280
NEXT SLIDE PLEASE.

1210
00:45:32,280 --> 00:45:35,880
FUTURE PLANS FOR THE RPA, IN OUR

1211
00:45:35,880 --> 00:45:38,160
WAY FORWARD, CURRENTLY RPA IS

1212
00:45:38,160 --> 00:45:39,920
WAITING FOR OUTCOME OF THE FDA,

1213
00:45:39,920 --> 00:45:42,960
TO BE APPROVED FOR CLINICAL USE,

1214
00:45:42,960 --> 00:45:44,720
THAT'S EXPECTED -- THAT RESULT

1215
00:45:44,720 --> 00:45:46,440
IS EXPECTED IN FEBRUARY, THE

1216
00:45:46,440 --> 00:45:48,120
PLAN TO TRY TO DEPLOY CLINICALLY

1217
00:45:48,120 --> 00:45:51,680
IN SOUTH AFRICA LATER ON THIS

1218
00:45:51,680 --> 00:45:54,880
YEAR, AND TO SCALE UP TO OTHER

1219
00:45:54,880 --> 00:45:56,200
LMICs WHILE SEEKING ADDITIONAL

1220
00:45:56,200 --> 00:45:58,480
FUNDING SUPPORT.

1221
00:45:58,480 --> 00:46:00,440
THE FUTURE PRACTICAL BENEFITS

1222
00:46:00,440 --> 00:46:01,640
DIRECTIONS FOR MAXIMUM BENEFIT

1223
00:46:01,640 --> 00:46:04,920
IS TO TRY TO INTEGRATE THE RPA

1224
00:46:04,920 --> 00:46:07,680
TO IMPROVE CLINICAL WORK FLOW,

1225
00:46:07,680 --> 00:46:09,320
LMIC STAFF NEED TO UNDERSTAND

1226
00:46:09,320 --> 00:46:14,520
PLANNING PROCESSES AND NEED

1227
00:46:14,520 --> 00:46:14,760
SKILLS.

1228
00:46:14,760 --> 00:46:16,520
EDUCATION WILL BE KEY BECAUSE WE

1229
00:46:16,520 --> 00:46:20,000
ALL NEED ABILITY TO CRITICALLY

1230
00:46:20,000 --> 00:46:21,120
APPRAISE RPA-GENERATED CONTOURS

1231
00:46:21,120 --> 00:46:22,720
AND PLANS.

1232
00:46:22,720 --> 00:46:24,400
WE NEED TO IDENTIFY PROS AND

1233
00:46:24,400 --> 00:46:26,800
CONS OF WEB BASED SOLUTIONS FOR

1234
00:46:26,800 --> 00:46:28,520
CENTERS, WE HAVE ALL VARIABLE

1235
00:46:28,520 --> 00:46:29,880
INTERNET, THE MAIN GOAL TO

1236
00:46:29,880 --> 00:46:31,600
IDENTIFY LONG-TERM SOLUTIONS TO

1237
00:46:31,600 --> 00:46:34,920
THE RPA INFRASTRUCTURE AND TO

1238
00:46:34,920 --> 00:46:37,520
MAINTAIN SUSTAINABILITY.

1239
00:46:37,520 --> 00:46:38,800
NEXT SLIDE PLEASE.

1240
00:46:38,800 --> 00:46:39,840
I WOULD LIKE TO THANK YOU FOR

1241
00:46:39,840 --> 00:46:40,880
YOUR TIME.

1242
00:46:40,880 --> 00:46:41,720
WE WELCOME ANY QUESTIONS.

1243
00:46:41,720 --> 00:46:45,240
THANK YOU VERY MUCH.

1244
00:46:45,240 --> 00:46:48,880
>> THANK YOU.

1245
00:46:48,880 --> 00:46:53,000
SO, THE TWO PRESENTATIONS ARE

1246
00:46:53,000 --> 00:46:55,200
OPEN FOR DISCUSSION.

1247
00:46:55,200 --> 00:46:58,360
>> I WOULD ALSO LIKE TO INVITE

1248
00:46:58,360 --> 00:46:59,920
ALL OF OUR GUESTS TO TURN ON

1249
00:46:59,920 --> 00:47:00,920
THEIR CAMERAS AND JOIN THE

1250
00:47:00,920 --> 00:47:05,560
DISCUSSION PLEASE.

1251
00:47:05,560 --> 00:47:07,440
 

1252
00:47:07,440 --> 00:47:09,480
>> YES, MARGARET?

1253
00:47:09,480 --> 00:47:11,480
>> FIRST OF ALL, DR. SIMMONS,

1254
00:47:11,480 --> 00:47:12,600
IT'S WONDERFUL TO SPEAK TO

1255
00:47:12,600 --> 00:47:13,880
SOMEONE WHO IS LIVING AND

1256
00:47:13,880 --> 00:47:16,200
WORKING IN THE COUNTRY OF MY

1257
00:47:16,200 --> 00:47:17,640
BIRTH, THAT I MISS VERY MUCH.

1258
00:47:17,640 --> 00:47:20,240
NUMBER TWO, I WAS JUST

1259
00:47:20,240 --> 00:47:23,280
WONDERING, YOU DID REFER TO IT

1260
00:47:23,280 --> 00:47:24,600
IN YOUR VERY LAST ONE OF THE

1261
00:47:24,600 --> 00:47:27,800
BULLETS, OF YOUR LAST SLIDE, THE

1262
00:47:27,800 --> 00:47:29,080
ISSUE IN SOUTH AFRICA, I HAVEN'T

1263
00:47:29,080 --> 00:47:31,960
BEEN BACK IN A LONG TIME BUT I

1264
00:47:31,960 --> 00:47:34,160
IMAGINE IT'S VERY DIFFERENT FROM

1265
00:47:34,160 --> 00:47:36,000
THE REST OF AFRICA, OR MOST

1266
00:47:36,000 --> 00:47:39,920
AFRICAN COUNTRIES IN TERMS OF

1267
00:47:39,920 --> 00:47:40,920
INTERNET ACCESS, HARDWARE,

1268
00:47:40,920 --> 00:47:44,160
SOFTWARE, EXPERTISE OF STAFF, SO

1269
00:47:44,160 --> 00:47:45,000
ON, WHERE THE PROGRAM SOUNDS

1270
00:47:45,000 --> 00:47:46,600
FANTASTIC AND WOULD BE A GREAT

1271
00:47:46,600 --> 00:47:49,880
ADDITION TO YOUR ARSENAL BUT I'M

1272
00:47:49,880 --> 00:47:50,680
WONDERING HOW MANY COUNTRIES ARE

1273
00:47:50,680 --> 00:47:52,520
AT A LEVEL THAT IT COULD BE

1274
00:47:52,520 --> 00:47:57,720
APPLIED  WITH AS WELL WITHIN THE

1275
00:47:57,720 --> 00:47:58,280
AFRICAN CONTINENT?

1276
00:47:58,280 --> 00:48:01,920
>> SO, IN THE PUBLIC SECTOR IN

1277
00:48:01,920 --> 00:48:03,960
SOUTH AFRICA PROBABLY AS WELL

1278
00:48:03,960 --> 00:48:05,000
RESOURCED WITH HUMAN CAPITAL AS

1279
00:48:05,000 --> 00:48:08,640
WE WOULD LIKE TO BE, WITH ONLY

1280
00:48:08,640 --> 00:48:10,840
40 ONCOLOGISTS TRYING TO DELIVER

1281
00:48:10,840 --> 00:48:12,280
CARE FOR 85% OF THE POPULATION,

1282
00:48:12,280 --> 00:48:15,520
BUT A LOT OF WORK HAS GONE INTO

1283
00:48:15,520 --> 00:48:16,720
ASKING EXACTLY THAT QUESTION SO

1284
00:48:16,720 --> 00:48:18,280
WE'RE WORKING WITH OUR

1285
00:48:18,280 --> 00:48:18,960
COLLEAGUES ACROSS THE CONTINENT

1286
00:48:18,960 --> 00:48:23,960
TO SAY WHAT ARE YOUR CHALLENGES,

1287
00:48:23,960 --> 00:48:26,120
WHAT ARE YOUR INFRASTRUCTURE

1288
00:48:26,120 --> 00:48:27,000
CHALLENGES, WHERE IS YOUR CT

1289
00:48:27,000 --> 00:48:28,000
SCANNER, WHAT TYPE OF

1290
00:48:28,000 --> 00:48:29,720
RADIOTHERAPY MACHINES DO YOU

1291
00:48:29,720 --> 00:48:30,120
HAVE?

1292
00:48:30,120 --> 00:48:31,680
SOMEHOW WE MAY WORK TOWARDS

1293
00:48:31,680 --> 00:48:33,680
TRYING TO MAKE THIS ACCESSIBLE

1294
00:48:33,680 --> 00:48:34,960
TO COBALT USERS, THOUGH COBALT

1295
00:48:34,960 --> 00:48:37,280
IS MUCH LESS USED ON THE

1296
00:48:37,280 --> 00:48:37,680
CONTINENT NOW.

1297
00:48:37,680 --> 00:48:40,560
IS ALMOST BEING PHASED OUT.

1298
00:48:40,560 --> 00:48:42,160
SO IT'S PART OF WHAT IS BEING

1299
00:48:42,160 --> 00:48:43,720
LOOKED AT, WHAT ARE THE REAL

1300
00:48:43,720 --> 00:48:46,920
CHALLENGES, HOW CAN WE WORK

1301
00:48:46,920 --> 00:48:50,400
AROUND THEM, WITH A MIXTURE

1302
00:48:50,400 --> 00:48:52,280
BETWEEN ON-SITE APR HARDWARE

1303
00:48:52,280 --> 00:48:53,000
STRUCTURE AND REMOTE STRUCTURE

1304
00:48:53,000 --> 00:48:55,240
FOR THOSE THAT HAVE ACCESS TO

1305
00:48:55,240 --> 00:48:55,480
INTERNET.

1306
00:48:55,480 --> 00:48:57,080
YOU WOULD BE SURPRISED HOW MANY

1307
00:48:57,080 --> 00:48:58,280
IN THE CONTINENT, PARTICULARLY

1308
00:48:58,280 --> 00:49:01,560
IN THE LAST TEN YEARS, REALLY

1309
00:49:01,560 --> 00:49:03,240
SCALED UP INFRASTRUCTURE WITH A

1310
00:49:03,240 --> 00:49:05,560
LOT OF FUNDING FROM

1311
00:49:05,560 --> 00:49:08,200
INTERNATIONAL FUNDERS, IAA,

1312
00:49:08,200 --> 00:49:08,960
THEIR OWN GOVERNMENTS

1313
00:49:08,960 --> 00:49:10,760
UNDERSTANDING CANCER NEEDS TO

1314
00:49:10,760 --> 00:49:14,560
GET ON THE AGENDA.

1315
00:49:14,560 --> 00:49:16,440
>> THANK YOU.

1316
00:49:16,440 --> 00:49:23,280
>> WE HAVE FOUND THAT A LOT OF 

1317
00:49:23,280 --> 00:49:24,360
GOVERNMENT PHILANTHROPIC

1318
00:49:24,360 --> 00:49:25,040
ORGANIZATIONS SPONSORED PURCHASE

1319
00:49:25,040 --> 00:49:28,880
AND INTEGRATE OF LINEAR

1320
00:49:28,880 --> 00:49:30,280
ACCELERATORS BUT DO NOT HAVE THE

1321
00:49:30,280 --> 00:49:31,640
SKILL SET TO KEEP THEM RUNNING

1322
00:49:31,640 --> 00:49:33,680
OR PLAN THE PATIENTS, THAT

1323
00:49:33,680 --> 00:49:35,040
INVESTMENT IS LARGELY WASTED,

1324
00:49:35,040 --> 00:49:37,160
REALLY UNFORTUNATE TO SEE

1325
00:49:37,160 --> 00:49:38,680
BUNKERS WITH LINEAR ACCELERATORS

1326
00:49:38,680 --> 00:49:41,000
EITHER NOT FULLY DEPLOYED OR

1327
00:49:41,000 --> 00:49:42,880
UTILIZED, DUE TO LACK OF

1328
00:49:42,880 --> 00:49:44,080
PERSONNEL AND TRAINED STAFF.

1329
00:49:44,080 --> 00:49:46,480
SO WE REALLY HOPE WE CAN

1330
00:49:46,480 --> 00:49:48,560
CAPITALIZE ON THOSE INVESTMENTS

1331
00:49:48,560 --> 00:49:50,640
AND MAKE THEM ACTUALLY

1332
00:49:50,640 --> 00:49:51,200
MEANINGFUL TO PATIENTS

1333
00:49:51,200 --> 00:49:53,280
THROUGHOUT THE CONTINENT AND

1334
00:49:53,280 --> 00:49:53,720
THROUGHOUT THE WORLD.

1335
00:49:53,720 --> 00:49:56,680
>> TO FOLLOW UP ON THAT, DR.

1336
00:49:56,680 --> 00:49:58,560
SIMMONS, YOU DID MENTION YOU'RE

1337
00:49:58,560 --> 00:50:00,160
WAITING FOR FDA APPROVAL.

1338
00:50:00,160 --> 00:50:02,960
IS THAT SOUTH AFRICAN FDA OR

1339
00:50:02,960 --> 00:50:04,920
U.S. FDA?

1340
00:50:04,920 --> 00:50:06,040
THE FIRST QUESTION, LET ME ASK

1341
00:50:06,040 --> 00:50:08,000
MY NEXT QUESTION, YOU CAN

1342
00:50:08,000 --> 00:50:09,080
ADDRESS BOTH.

1343
00:50:09,080 --> 00:50:11,280
AND THE NEXT PHASE, WHEN YOU DO

1344
00:50:11,280 --> 00:50:16,600
A LARGER SCALE CLINICAL TESTING,

1345
00:50:16,600 --> 00:50:19,760
DO YOU PLAN TO -- MARGARET'S

1346
00:50:19,760 --> 00:50:21,680
QUESTION, TO DO SOME -- INCLUDE

1347
00:50:21,680 --> 00:50:24,440
SOME CENTERS OUTSIDE OF SOUTH

1348
00:50:24,440 --> 00:50:24,680
AFRICA?

1349
00:50:24,680 --> 00:50:26,480
>> SO, THE FIRST QUESTION ABOUT

1350
00:50:26,480 --> 00:50:29,640
THE FDA IS THAT IT'S U.S. FDA,

1351
00:50:29,640 --> 00:50:32,760
BUT DR. CORK WILL SPEAK MORE

1352
00:50:32,760 --> 00:50:33,320
ABOUT THAT.

1353
00:50:33,320 --> 00:50:36,480
OUR OWN RULES FOR IMPLEMENTATION

1354
00:50:36,480 --> 00:50:41,200
SOUTH AFRICA MAY DIFFER THAN THE

1355
00:50:41,200 --> 00:50:41,680
FDA OBLIGATIONS.

1356
00:50:41,680 --> 00:50:44,480
AND YES, DR. CORK WILL WORK WITH

1357
00:50:44,480 --> 00:50:47,600
MANY PEOPLE ACROSS THE

1358
00:50:47,600 --> 00:50:49,960
CONTINENT, THE PLAN TO BE

1359
00:50:49,960 --> 00:50:54,320
DEPLOYED TO OTHER COUNTRIES WITH

1360
00:50:54,320 --> 00:50:54,920
THE MINIMUM INFRASTRUCTURE

1361
00:50:54,920 --> 00:50:55,840
NEEDED, REAL STAFF ARE BEYOND

1362
00:50:55,840 --> 00:50:57,160
THE NORTH AND SOUTH.

1363
00:50:57,160 --> 00:51:00,880
IT'S EAST, WEST, MIDDLE THAT

1364
00:51:00,880 --> 00:51:01,880
REALLY NEED RPA-TYPE TECHNOLOGY

1365
00:51:01,880 --> 00:51:04,720
TO BE SUCCESSFUL TREATING THEIR

1366
00:51:04,720 --> 00:51:05,000
PATIENTS.

1367
00:51:05,000 --> 00:51:08,080
>> I CAN SAY SOMETHING ABOUT THE

1368
00:51:08,080 --> 00:51:08,240
FDA.

1369
00:51:08,240 --> 00:51:10,200
SO IT'S -- WE'RE GOING THROUGH

1370
00:51:10,200 --> 00:51:11,440
THE FDA, THE AMERICAN FDA, BUT

1371
00:51:11,440 --> 00:51:13,720
THE REAL REASON IS TO GIVE US

1372
00:51:13,720 --> 00:51:16,320
CREDIBILITY AND IT SHOWS THAT WE

1373
00:51:16,320 --> 00:51:18,840
HAVE LIKE THE RISK MANAGEMENT,

1374
00:51:18,840 --> 00:51:20,160
QUALITY MANAGEMENT, ALL OF

1375
00:51:20,160 --> 00:51:21,400
THOSE, SOFTWARE LIFE CYCLE, ALL

1376
00:51:21,400 --> 00:51:23,560
THOSE PROCESSES THAT YOU NEED TO

1377
00:51:23,560 --> 00:51:25,520
CREATE THE SOFTWARE DEVICE FOR

1378
00:51:25,520 --> 00:51:28,480
MEDICAL USE SHOWS WE HAVE THEM

1379
00:51:28,480 --> 00:51:30,160
IN PLACE, SO IT SHOWS PEOPLE,

1380
00:51:30,160 --> 00:51:32,560
ALSO MAKES SURE WE DO HAVE THEM

1381
00:51:32,560 --> 00:51:32,880
IN PLACE.

1382
00:51:32,880 --> 00:51:35,280
IN TERMS OF SOUTH AFRICA, WE

1383
00:51:35,280 --> 00:51:37,920
HAVE ALL THE LEGAL -- WE'VE HAD

1384
00:51:37,920 --> 00:51:39,360
CONSULTANTS HELP US WITH THE

1385
00:51:39,360 --> 00:51:41,280
LEGAL, WE'RE IN PRETTY GOOD

1386
00:51:41,280 --> 00:51:43,080
POSITION FOR SOUTH AFRICA, AND

1387
00:51:43,080 --> 00:51:44,680
OUR GOAL IS TO TREAT IN SOUTH

1388
00:51:44,680 --> 00:51:49,840
AFRICA AT THE END OF THIS YEAR,

1389
00:51:49,840 --> 00:51:52,320
AS DR.SIMMONS SAID, AND WHEN

1390
00:51:52,320 --> 00:51:53,080
PEOPLE USE THIS CLINICALLY CAN

1391
00:51:53,080 --> 00:51:54,680
PAY A CAREFUL LOOK AT WHAT RISKS

1392
00:51:54,680 --> 00:51:58,280
AND HOW PEOPLE USE IT, THAT WE

1393
00:51:58,280 --> 00:51:59,680
HAVEN'T -- WE DON'T KNOW YET,

1394
00:51:59,680 --> 00:52:04,480
THE IDEA IS TO SCALE BASED ON

1395
00:52:04,480 --> 00:52:04,880
THAT EXPERIENCE.

1396
00:52:04,880 --> 00:52:06,960
YEAH, ABSOLUTELY WE'LL BE

1397
00:52:06,960 --> 00:52:08,720
SCALING ELSEWHERE AS WELL.

1398
00:52:08,720 --> 00:52:11,480
>> ANY OTHER QUESTIONS?

1399
00:52:11,480 --> 00:52:15,800
 

1400
00:52:15,800 --> 00:52:16,040
 

1401
00:52:16,040 --> 00:52:19,960
WELL, LET ME THEN -- DR. SAMIR,

1402
00:52:19,960 --> 00:52:21,040
VERY INTERESTING PRESENTATION.

1403
00:52:21,040 --> 00:52:23,520
I HAVE TWO QUESTIONS.

1404
00:52:23,520 --> 00:52:28,080
YOU DID MENTION THAT YOU ARE

1405
00:52:28,080 --> 00:52:31,880
ALSO -- IN ADDITION TO PUNCH

1406
00:52:31,880 --> 00:52:33,400
BIOPSIES GOING TO USE LIQUID

1407
00:52:33,400 --> 00:52:33,680
BIOPSIES.

1408
00:52:33,680 --> 00:52:36,280
I WONDER WHAT TYPE OF LIQUID

1409
00:52:36,280 --> 00:52:36,800
BIOPSY AND WHAT MARKER?

1410
00:52:36,800 --> 00:52:40,720
IS IT TO LOOK FOR THE VIRUS OR

1411
00:52:40,720 --> 00:52:46,320
SOME OTHER BIOMARKER? 

1412
00:52:46,320 --> 00:52:48,800
>> YES, SO THE LIQUID BIOPSY

1413
00:52:48,800 --> 00:52:52,280
IDEA IS -- YOU CAN THINK ABOUT

1414
00:52:52,280 --> 00:52:56,880
IT TWO WAYS.

1415
00:52:56,880 --> 00:52:58,480
FIRST, THE --

1416
00:52:58,480 --> 00:53:01,000
[AUDIO DISTORTION]

1417
00:53:01,000 --> 00:53:05,240
 

1418
00:53:05,240 --> 00:53:07,720
THE RNA, SORT OF --

1419
00:53:07,720 --> 00:53:12,520
[AUDIO DISTORTION] 

1420
00:53:12,520 --> 00:53:13,880
BUT THAT'S --

1421
00:53:13,880 --> 00:53:17,800
[AUDIO DISTORTION] 

1422
00:53:17,800 --> 00:53:19,560
YEAH, THAT'S I THINK THE IDEA

1423
00:53:19,560 --> 00:53:23,480
THAT WE WERE TRYING TO PUSH 

1424
00:53:23,480 --> 00:53:25,360
ALONG WITH THIS, SO IT'S --

1425
00:53:25,360 --> 00:53:29,560
[AUDIO DISTORTION]

1426
00:53:29,560 --> 00:53:30,520
 

1427
00:53:30,520 --> 00:53:30,800
>> OKAY.

1428
00:53:30,800 --> 00:53:32,680
QUICKLY, TINY, THE INSTRUMENT,

1429
00:53:32,680 --> 00:53:35,280
WHAT'S THE READOUT YOU HAVE?

1430
00:53:35,280 --> 00:53:36,360
QUANTITATIVE OR QUALITATIVE?

1431
00:53:36,360 --> 00:53:39,240
YES OR NO?

1432
00:53:39,240 --> 00:53:41,080
 

1433
00:53:41,080 --> 00:53:42,640
>> QUANTITATIVE READ.

1434
00:53:42,640 --> 00:53:48,400
AND WE NEEDED THAT TO ENABLE

1435
00:53:48,400 --> 00:53:52,760
US -- YOU KNOW, DEVELOP THE

1436
00:53:52,760 --> 00:53:56,240
CUT-POINTS OF THE QUALITATIVE.

1437
00:53:56,240 --> 00:53:57,920
MY COLLEAGUE, DAVID, IS THE

1438
00:53:57,920 --> 00:53:59,520
BETTER ENGINEER AT THIS AND HE

1439
00:53:59,520 --> 00:54:00,960
MAY BE ABLE TO ARTICULATE IN

1440
00:54:00,960 --> 00:54:02,720
MORE SPECIFIC TERMS THAN ME.

1441
00:54:02,720 --> 00:54:05,040
DAVID, DO YOU WANT TO SAY

1442
00:54:05,040 --> 00:54:06,640
SOMETHING?

1443
00:54:06,640 --> 00:54:07,200
>> YEP.

1444
00:54:07,200 --> 00:54:09,040
EXCUSE ME, YEP.

1445
00:54:09,040 --> 00:54:10,520
WE-- IT IS QUANTITATIVE, THE

1446
00:54:10,520 --> 00:54:13,120
RESULT IS QUANTITATIVE, AND WE

1447
00:54:13,120 --> 00:54:15,960
USE THAT QUANTITATIVE RESULT,

1448
00:54:15,960 --> 00:54:18,480
SORT OF AMOUNT OF DNA IN THE

1449
00:54:18,480 --> 00:54:19,320
BIOPSY TO SET CUT-POINTS ABOVE

1450
00:54:19,320 --> 00:54:24,040
WHICH WE CAN CALL IT CANCER AND

1451
00:54:24,040 --> 00:54:25,840
BELOW WHICH WE CAN CALL IT NOT

1452
00:54:25,840 --> 00:54:27,240
CANCER.

1453
00:54:27,240 --> 00:54:30,960
>> OKAY.

1454
00:54:30,960 --> 00:54:34,200
ANY OTHER QUESTIONS?

1455
00:54:34,200 --> 00:54:38,360
 

1456
00:54:38,360 --> 00:54:39,480
WELL, THAT'S VERY FASCINATING,

1457
00:54:39,480 --> 00:54:42,120
TWO EXCELLENT EXAMPLES OF WHAT

1458
00:54:42,120 --> 00:54:43,520
THE AFFORDABLE CANCER

1459
00:54:43,520 --> 00:54:48,440
TECHNOLOGIES PROGRAM CAN DO.

1460
00:54:48,440 --> 00:54:52,200
AND AT THIS JUNCTURE, NED, ARE

1461
00:54:52,200 --> 00:54:54,120
YOU STILL ON?

1462
00:54:54,120 --> 00:54:58,600
DR. SHARPLESS?

1463
00:54:58,600 --> 00:54:59,480
I THINK HE HAS COMPUTER

1464
00:54:59,480 --> 00:55:00,000
PROBLEMS.

1465
00:55:00,000 --> 00:55:02,360
>> I HOPE HE CAN FIX HIS

1466
00:55:02,360 --> 00:55:03,440
COMPUTER ISSUE BEFORE THE

1467
00:55:03,440 --> 00:55:04,240
AFTERNOON.

1468
00:55:04,240 --> 00:55:05,040
>> YEAH.

1469
00:55:05,040 --> 00:55:07,640
OKAY.

1470
00:55:07,640 --> 00:55:11,520
 

1471
00:55:11,520 --> 00:55:13,320
WELL, THE -- SO ANY CLOSING

1472
00:55:13,320 --> 00:55:17,240
COMMENTS, SATISH?

1473
00:55:17,240 --> 00:55:18,320
>> NO, IT'S GREAT TO ALWAYS

1474
00:55:18,320 --> 00:55:19,440
INTERACT WITH THE SUBCOMMITTEE

1475
00:55:19,440 --> 00:55:21,160
AND THANKS FOR THE OPPORTUNITY

1476
00:55:21,160 --> 00:55:23,920
TO HIGHLIGHT SOME OF THE WORK

1477
00:55:23,920 --> 00:55:24,840
THE AFFORDABLE CANCER

1478
00:55:24,840 --> 00:55:25,760
TECHNOLOGIES PROGRAM HAS

1479
00:55:25,760 --> 00:55:28,080
SUPPORTED.

1480
00:55:28,080 --> 00:55:30,840
>> WELL, WE'RE RIGHT ON 12:45,

1481
00:55:30,840 --> 00:55:32,760
RIGHT ON TIME.

1482
00:55:32,760 --> 00:55:34,920
AND I THINK WITH THAT WE WILL

1483
00:55:34,920 --> 00:55:35,280
ADJOURN.

1484
00:55:35,280 --> 00:55:39,880
AND THANK YOU ALL FOR COMING.

1485
00:55:39,880 --> 00:55:41,400
>> NCAB SUBCOMMITTEE MEETING HAS

1486
00:55:41,400 --> 00:55:41,680
CONCLUDED.

1487
00:55:41,680 --> 00:55:43,720
WE'LL NOW TRANSITION TO THE NCAB

1488
00:55:43,720 --> 00:55:44,680
OPEN SESSION THAT WILL BEGIN AT

1489
00:55:44,680 --> 00:55:45,480
ONE P.M. ON SEPARATE VIDEOCAST.

1490
00:55:45,480 --> 00:55:49,360
THIS VIDEOCAST SESSION WILL NOW

1491
00:55:49,360 --> 00:00:00,000
END.